Materials and methods for gene therapy

Abstract

The subject invention concerns materials and methods for gene therapy. One aspect of the invention pertains to vectors which can be used to effect genetic therapy in animals or humans having genetic disorders where expression of high levels of a protein of interest are required to treat or correct the disorder. The subject invention also pertains to methods for treating animals or humans in need of gene therapy to treat or correct a genetic disorder. The materials and methods of the invention can be used to provide therapeutically effective levels of a protein that is non-functional, or that is absent or deficient in the animal or human to be treated. In one embodiment, the materials and methods can be used to treat alpha-1-antitrypsin deficiency.

Description

BACKGROUND OF THE INVENTION

Alpha-1-antitrypsin (AAT) deficiency is the second most common monogenic lung disease in man, accounting for approximately 3% of all early deaths due to obstructive pulmonary disease. AAT protein is normally produced in the liver, secreted into the serum and circulated to the lung where it protects the fine supporting network of elastin fibers from degradation by neutrophil elastase. Current therapy for AAT deficiency includes avoidance of cigarette smoke exposure and weekly intravenous infusions of recombinant human AAT (hAAT) protein. Attempts to devise gene therapy strategies to replace AAT either in the lung itself or within any of a number of other tissues which are capable of AAT secretion have been limited by the short duration of expression from some vectors and by the relatively high circulating levels of AAT which is required for therapeutic effect. Methods of gene therapy have been described in U.S. Pat. No. 5,399,346.

It has recently been demonstrated that adeno-associated virus (AAV) vectors are capable of stable in vivo expression and may be less immunogenic than other viral vectors (Flotte et al., 1996; Xiao et al., 1996; Kessler et al., 1996; Jooss et al., 1998). AAV is a non-pathogenic human parvovirus whose life cycle naturally includes a mechanism for long-term latency. In the case of wild-type AAV (wtAAV), this persistence is due to site-specific integration into a site on human chromosome 19 (the AAVSI site) in the majority of cells (Kotin et al., 1990), whereas with recombinant AAV (rAAV) vectors, persistence appears to be due to a combination of episomal persistence and integration into non-chromosome 19 locations (Afione et al., 1996; Kearns et al., 1996). Recombinant AAV latency also differs from that of wtAAV in that wtAAV is rapidly converted to double-stranded DNA in the absence of helper virus (e.g., adenovirus) infection, while with rAAV leading strand synthesis is delayed in the absence of helper virus (Fisher et al., 1996; Ferrari et al., 1996). U.S. Pat. No. 5,658,785 describes adeno-associated virus vectors and methods for gene transfer to cells.

Kessler et al. (1996) demonstrated that murine skeletal myofibers transduced by an rAAV vector were capable of sustained secretion of biologically active human erythropoietin (hEpo), apparently without eliciting a significant immune response against the secreted hEpo. See also U.S. Pat. No. 5,858,351 issued to Podsakoff et al. Likewise, Murphy et al. (1997) have observed the expression and secretion of sustained levels of leptin in ob/ob mice after AAV muscle transduction. Brantly et al. (U.S. Pat. No. 5,439,824) disclose methods for increasing expression of AAT using vectors comprising intron II of the human AAT gene. However, the level of leptin expression observed was only in the range of 2 to 5 ng/ml. Therapy for AAT deficiency requires serum levels of at least about 800 μg/ml. Thus, there remains a need in the art for a means of providing therapeutically beneficial levels of a protein to a person in need of such treatment.

BRIEF SUMMARY OF THE INVENTION

The subject invention concerns materials and methods for gene therapy. One aspect of the invention pertains to vectors which can be used to provide genetic therapy in animals or humans having a genetic disorder where relatively high levels of expression of a protein is required to treat the disorder. The vectors of the invention are based on adeno-associated virus (AAV). The vectors are designed to provide high levels of expression of heterologous DNA contained in the vector. In one embodiment, the vectors comprise AAV inverted terminal repeat sequences and constitutive or regulatable promoters for driving high levels of gene expression. The subject invention also pertains to methods for treating animals or humans in need of gene therapy, e.g., to correct a genetic deficiency disorder.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows rAAV-AAT vector cassettes used according to the subject invention. The A-AT and B-AT constructs contain the promoters from the small nuclear RNA genes, U1a and U1b, respectively. The C-AT construct contains the CMV promoter, whereas the E-AT vector uses the human elongation factor 1-α (ELF in the figure) promoter. ITR refers to AAV inverted terminal repeat; An refers to polyA signal; Tk refers to the HSV thymidine kinase promoter; neo refers to the Tn5 neomycin phosphotransferase gene.

FIG. 2 shows hAAT secretion rates in vitro from transiently transfected murine C2C12 myoblast cell line using expression vectors according to the subject invention. C-AT does not differ significantly from E-AT, but both differ from A-AT and B-AT (p<0.05) AAT expression was detected using an ELISA assay specific for human AAT.

FIG. 3 shows hAAT secretion rates in vitro from stably transduced murine C2C12 myoblast cell line using viral particles comprising expression vectors according to the subject invention. The mean rates of secretion from G418-resistant cultures 1 mo after transduction with either packaged E-AT vector or packaged C-AT vector are shown. In each instance, a “low” multiplicity transduction (4×10 5 particles/cell) and a high multiplicity transduction (4×10 6 particles/cell) were performed. E-AT “low” and “high” are greater than “high” multiplicity C-AT (P=0.02) but are not significantly different from each other (n=3). AAT expression was detected using an ELISA assay specific for human AAT.

FIG. 4 shows additional constructs tested for hAAT expression. The murine myoblast C2C12 cells were grown in 35-mm Wells with approximately 4×10 5 cell per well and were transfected with 5 μg of the appropriate plasmid DNA using SUPERFECT transfection (Qiagen Inc., CA). Secretion of hAAT into the medium was assessed at 2 days after transfection using an antigen-capture ELISA. Each bar represents the mean of results from three experiments (triplicate in each experiment). Data from transfection experiments indicate that the expression from p43CB-AT was at least three times higher than that from C-AT in vitro.

FIGS. 5A and 5B show sustained secretion of therapeutic levels of hAAT using either the C-AT vector or the E-AT vector in either SCID or C57BL mice. FIG. 5A shows the mean total serum levels of hAAT observed in groups of either SCID (squares) or C57BL (circles) mice receiving either low dose (5×10 11 particles) (open symbols) or high dose (1.4×10 13 particles) (filled symbols) single injections into muscle of the C-AT vector measured at time points ranging from 1 to 16 wk after injection. For each strain, the high-dose curve is significantly different from the low-dose curve (P=0.009 for SCID, P=0.02 for C57BL), but the strains do not differ from each other. FIG. 5B shows analogous data with the E-AT vector. None of these differences were significant.

FIG. 5C shows long term secretion of hAAT from murine muscle transduced with C-AT. C57B1/6 or C57B1/6-SCID mice received 3.5×10 10 IU, 1.4×10 13 particles/mouse. One year after injection, serum hAAT levels were still 400 μg/ml in C57B1/6-SCID and 200 μg/ml in C57B1/6. This level are comparable with the peak levels observed (800 or 400 μg/ml, respectively).

FIG. 6 shows an immunoblot of sera taken from several of the C-AT vector-treated mice at 11 weeks after vector administration. Ten microliters of a 1:100 dilution of serum was electrophoresed by 10% SDS/PAGE, blotted, and incubated with 1:1,500 dilution of goat anti-hAAT-horseradish peroxidase conjugate (Cappel/ICN). Samples from three high-dose SCID (h1-h3), one high-dose C57B1 (h3), and three low-dose C57B1 (lo1-lo3) were included, along with one negative control (saline-injected=sal) serum to indicate the level of reactivity with endogenous mAAT. As a standard, hAAT was added either to negative-control C57B1 serum (first hAAT lane) or to PBS (second hAAT) lane to final equivalent serum concentration of 100 μg/ml.

FIGS. 7A and 7B show that some BALB/c mice mount humoral immune responses to hAAT, which correlate with lower serum levels but no observable toxicity. FIG. 7A shows serum hAAT levels and FIG. 7B shows serum anti-hAAT antibody levels as determined by ELISA performed on serum taken from mice injected with 1×10 11 particles of the C-AT vector. Each set of symbols represents an individual animal (□, no. 1; Δ, no. 2; ∘, no. 3). Note the inverse correlation between the presence of antibody and the presence of circulating hAAT.

FIG. 8 shows the persistence of rAAV-AAT vector DNA in high molecular weight form. PCR products were amplified from DNA prepared by Hirt extraction from three SCID mice injected 16 wk earlier with 5×10 11 resistant-particles of C-AT and analyzed by Southern blot. The high molecular weight Hirt pellet (genomic DNA lanes) and the low molecular weight supernatant (episomal DNA lanes) were analyzed separately. Control lanes include a sample in which an hAAT cDNA plasmid was the template DNA (+) and a control in which water was the template (−). In this internal PCR reaction, a 500-bp product is expected regardless of whether or not the vector genome is integrated.

FIG. 9 shows serum hAAT in C57B1/6 mice transduced with C-AT and p43CB-AT. C57B1/6 mice were injected in muscle with C-AT (3.5×10 10 IU/mouse, 1×10 12 particles/mouse) or p43CB-AT (6×10 9 UI, 1×10 12 particles/mouse). The level of hAAT from p43CB-AT were projected based on an estimation of the equivalent dosage (infectious unit) of C-AT.

FIG. 10 shows enhancement of CMV promoter activity by a synthetic enhancer in C2C12 cells. The murine myoblast C2C12 cells were grown in 35-mm wells with approximately 4×10 5 cell per well and were transfected with 5 μg of p43rmsENC-AT vector DNA using SUPERFECT transfection (Qiagen Inc, CA). Secretion of hAAT into the medium was assessed at 2 days after transfection using an antigen-capture ELISA. Each bar represents the mean of results from one experiment (triplicate).

FIG. 11 shows secretion of hAAT from mouse liver cells (HO15) transfected with different constructs. The murine liver cells (HO15) were grown in 35-mm wells with approximately 4×10 5 cell per well and were transfected with 5 μg of the plasmid DNA using LIPOFECTAMINE reagents (Life Technologies Inc, MD). Secretion of hAAT into the medium was assessed at 2 days after transfection using an antigen-capture ELISA. Each bar represents the mean of results from two experiments (triplicate).

FIG. 12 shows secretion of HAAT from mouse liver cells (HO15) transfected using different methods. The murine liver cells (HO15) were grown in 35-mm wells with approximately 4×10 5 cell per well and were transfected with 5 μg of the p43CB-AT vector using SUPERFECT (Qiagen Inc., CA), FuGENE (Boehringer Mannhem Co, IN), Lipofectin, LIPOFECTAMINE (Life Technologies Inc, MD) reagents and Calcium phosphate (CA-PO4) transfection. Secretion of hAAT into the medium was assessed at 2 days after transfection using an antigen-capture ELISA. Each bar represents the mean of results from one experiment (triplicate).

FIG. 13 shows HAAT secretion from mouse liver transduced with rAAV. C57B1/6 mice were injected with either p43CB-AT, C-AT or E-AT vector either by portal vein or tail vein injection. PV=portal vein injection. TV=tail vein injection.

FIG. 14 shows serum hAAT levels in C57B1/6 mice after intratracheal (IT) injection of C-AT or p43CB-AT vector. Mice received either 10 9 IU of C-AT (open circles), 10 9 IU of p43CB-AT (open triangles) or 10 10 IU of p43CB-AT (open squares).

FIG. 15 and FIGS. 15A-15C shows a map and nucleotide sequence for the vector of the present invention designated as C-AT (SEQ ID NO:1).

FIG. 16 and FIGS. 16A-16C shows a map and nucleotide sequence for the vector of the present invention designated as E-AT (SEQ ID NO:2).

FIG. 17 and FIGS. 17A-17C shows a map and nucleotide sequence for the vector of the present invention designated as dE-AT (SEQ ID NO:3).

FIG. 18 and FIGS. 18A-18C shows a map and nucleotide sequence for the vector of the present invention designated as p43C-AT (SEQ ID NO:4).

FIG. 19 and FIGS. 19A-19C shows a map and nucleotide sequence for the vector of the present invention designated as p43C-AT-IN (SEQ ID NO:5). This vector includes intron II from human AAT gene to enhance transcription.

FIG. 20 and FIGS. 20A-20C shows a map and nucleotide sequence for the vector of the present invention designated as p43CB-AT (SEQ ID NO:6).

FIG. 21 and FIGS. 21A-20C shows a map and nucleotide sequence for the vector of the present invention designated as C-AT2 (SEQ ID NO:7).

FIG. 22 and FIGS. 22A-22C shows a map and nucleotide sequence for the vector of the present invention designated as p43msENC-AT (SEQ ID NO:8). This vector is similar to p43C-AT but also comprises an enhancer sequence upstream of the CMV promoter.

FIG. 23 and FIGS. 23A-23C shows a map and nucleotide sequence for the vector of the present invention designated as p43rmsENC-AT (SEQ ID NO:9). This vector is the same as the p43msENC-AT vector except that the enhancer sequence is in an opposite orientation.

FIG. 24 and FIGS. 24A-24C shows a map and nucleotide sequence for the vector of the present invention designated as p43msENCB-AT (SEQ ID NO:10). This vector is similar to p43CB-AT but also comprises an enhancer sequence upstream of the CMV promoter.

FIG. 25 and FIGS. 25A-25C shows a map and nucleotide sequence for the vector of the present invention designated as p43rmsENCB-AT (SEQ ID NO:11). This vector is the same as p43msENCB-AT except that the enhancer sequence is in an opposite orientation.

DETAILED DESCRIPTION OF THE INVENTION

The subject invention pertains to novel materials and methods for providing gene therapy to a mammal or human having a condition or disorder, such as genetic deficiency disorders, where high levels of expression of a protein are required to treat the disorder or condition. In one method of the subject invention, a viral vector is introduced into cells of an animal wherein a therapeutic protein is produced, thereby providing genetic therapy for the animal. In one embodiment, a method of the invention comprises introducing into an animal cell or tissue an effective amount of viral particles or vector comprising a recombinant genome which includes heterologous polynucleotide encoding a protein useful in genetic therapy and that can be expressed by the cell or tissue. Expression of the heterologous polynucleotide results in production of the protein. Preferably, the therapeutic protein encoded by the heterologous polynucleotide is a serum protein. In a preferred embodiment, vector material comprising the heterologous polynucleotide is integrated into a chromosome of the cell of the host animal.

In one embodiment, a recombinant polynucleotide vector of the present invention is derived from adeno-associated virus (AAV) and comprises a constitutive or regulatable promoter capable of driving sufficient levels of expression of the heterologous DNA in the viral vector. Preferably, a recombinant vector of the invention comprises inverted terminal repeat sequences of AAV, such as those described in WO 93/24641. In a preferred embodiment, a vector of the present invention comprises polynucleotide sequences of the pTR-UF5 plasmid. The pTR-UF5 plasmid is a modified version of the pTR BS -UF/UF1/UF2/UFB series of plasmids (Zolotukhin et al., 1996; Klein et al., 1998). The pTR-UF5 plasmid contains modifications to the sequence encoding the green fluorescent protein (GFP).

Promoters useful with the subject invention include, for example, the cytomegalovirus immediate early promoter (CMV), the human elongation factor 1-alpha promoter (EF1), the small nuclear RNA promoters (U1a and U1b), α-myosin heavy chain promoter, Simian virus 40 promoter (SV40), Rous sarcoma virus promoter (RSV), adenovirus major late promoter, β-actin promoter and hybrid regulatory element comprising a CMV enhancer/β-actin promoter. These promoters have been shown to be active in a wide range of mammalian cells.

The promoters are operably linked with heterologous DNA encoding the protein of interest. By “operably linked,” it is intended that the promoter element is positioned relative to the coding sequence to be capable of effecting expression of the coding sequence.

Promoters particularly useful for expression of a protein in muscle cells include, for example, hybrid CMV enhancer/β-actin promoters, CMV promoters, synthetic promoters and EF1 promoter. Promoters particularly useful for expression of a protein in liver cells include, for example, hybrid CMV enhancer/β-actin promoters and EF1 promoters.

Also contemplated for use with the vectors of the present invention are inducible and cell type specific promoters. For example, Tet-inducible promoters (Clontech, Palo Alto, Calif.) and VP16-LexA promoters (Nettelbeck et al., 1998) can be used in the present invention.

The vectors can also include introns inserted into the polynucleotide sequence of the vector as a means for increasing expression of heterologous DNA encoding a protein of interest. For example, an intron can be inserted between a promoter sequence and the region coding for the protein of interest on the vector. Introns can also be inserted in the coding regions. Exemplified in the present invention is the use of intron II from the hAAT gene in a subject vector. Transcriptional enhancer elements which can function to increase levels of transcription from a given promoter can also be included in the vectors of the invention. Enhancers can generally be placed in either orientation, 3′ or 5′, with respect to promoter sequences. In addition to the natural enhancers, synthetic enhancers can be used in the present invention. For example, a synthetic enhancer randomly assembled from Spc5-12-derived elements including muscle-specific elements, serum response factor binding element (SRE), myocyte-specific enhancer factor-1 (MEF-1), myocyte-specific enhancer factor-2 (MEF-2), transcription enhancer factor-1 (TEF-1) and SP-1 (Li et al., 1999; Deshpande et al., 1997; Stewart et al., 1996; Mitchell et al., 1989; Briggs et al., 1986; Pitluk et al., 1991) can be used in vectors of the invention.

Heterologous polynucleotide in the recombinant vector can include, for example, polynucleotides encoding normal, functional proteins which provide therapeutic replacement for normal biological function in animals afflicted with genetic disorders which cause the animal to produce a defective protein, or abnormal or deficient levels of that protein. Proteins, and the polynucleotide sequences that encode them, which can be provided by gene therapy using the subject invention include, but are not limited to, anti-proteases, enzymes, structural proteins, coagulase factors, interleukins, cytokines, growth factors, interferons, and lymphokines. In an exemplified embodiment, heterologous DNA in a recombinant AAV vector encodes human alpha-1-antitrypsin protein.

As those of ordinary skill in the art will appreciate, any of a number of different nucleotide sequences can be used, based on the degeneracy of the genetic code, to produce a protein of interest for use in the present invention. Accordingly, any nucleotide sequence which encodes a protein of interest comes within the scope of this invention. Biologically active fragments and variants of a protein of interest can easily and routinely be produced by techniques well known in the art. For example, time-controlled Bal31 exonuclease digestion of the full-length DNA followed by expression of the resulting fragments and routine screening can be used to readily identify expression products having the desired activity (Wei et al., 1993).

As used herein, the terms “polynucleotide” and “polynucleotide sequence” refer to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, would encompass known analogs of natural nucleotides that can function in a similar manner as naturally-occurring nucleotides. Polynucleotide sequences can include both DNA strand sequences, such as that which is transcribed into RNA, and RNA sequences. The polynucleotide sequences include both full-length sequences as well as shorter sequences derived from the full-length sequences. It is understood that a particular polynucleotide sequence includes sequences, such as degenerate codons of the native sequence or sequences, which may be introduced to provide codon preference in a specific host cell. Polynucleotides of the invention encompass both the sense and antisense strands as either individual strands or in the duplex.

The polynucleotides of the subject invention also encompass equivalent and variant sequences containing mutations in the exemplified sequences. These mutations can include, for example, nucleotide substitutions, insertions, and deletions as long as the variant sequence functions in a manner similar to the exemplified sequences.

The gene therapy methods of the invention can be performed by ex vivo or in vivo treatment of the patient's cells or tissues. Cells and tissues contemplated within the scope of the invention include, for example, muscle, liver, lung, skin and other cells and tissues that are capable of producing and secreting serum proteins. The vectors of the invention can be introduced into suitable cells, cell lines or tissue using methods known in the art. The viral particles and vectors can be introduced into cells or tissue in vitro or in vivo. Methods contemplated include transfection, transduction, injection and inhalation. For example, vectors can be introduced into cells using liposomes containing the subject vectors, by direct transfection with vectors alone, electroporation or by particle bombardment. In an exemplified embodiment, muscle cells are infected in vivo by injection of viral particles comprising recombinant vector into muscle tissue of an animal. In another embodiment, liver cells are infected in vivo by injection of recombinant virus into either the portal vein or peripheral veins.

The methods and materials of the subject invention can be used to provide genetic therapy for any conditions or diseases treatable by protein or cytokine infusion such as, for example, alpha-1-antitrypsin deficiency, hemophilia, adenosine deaminase deficiency, and diabetes. The methods and materials of the subject invention can also be used to provide genetic therapy for treating conditions such as, for example, cancer, autoimmune diseases, neurological disorders, immunodeficiency diseases, and bacterial and viral infections. For example, the present invention can be used to provide genetic therapy to a patient wherein cells from the patient are transformed to express and produce interleukins such as interleukin-2.

Using the materials and methods of the subject invention, the skilled artisan can for the first time provide therapeutically effective levels of a serum protein through genetic therapy. In a preferred embodiment, the therapeutically effective level of serum protein that can be obtained using the subject materials and methods is at least about 1 μg/ml of protein in serum. Preferably, the level of serum protein that can be obtained using the present invention is at least about 100 μg/ml of protein in the serum. Most preferably, the level of serum protein that can be obtained by the present invention is at least about 500 μg/ml of protein in the serum.

Animals that can be treated with the materials and methods of the invention include mammals such as bovine, porcine, equine, ovine, feline and canine mammals. Preferably, the mammals are primates such as chimpanzees and humans.

The subject invention also concerns cells containing recombinant vectors of the present invention. The cells can be, for example, animal cells such as mammalian cells. Preferably, the cells are human cells. More preferably, the cells are human myofibers or myoblasts, hepatocytes or lung cells. In a preferred embodiment, a recombinant vector of the present invention is stably integrated into the host cell genome. Cell lines containing the recombinant vectors are also within the scope of the invention.

In an exemplified embodiment, recombinant AAV vectors comprising the human AAT gene (hAAT) using either the CMV promoter (AAV-C-AT) or the human elongation factor 1-alpha (EF1) promoter (AAV-E-AT) to drive expression were constructed and packaged using standard techniques. A murine myoblast cell line, C2C12, was transduced with each vector and expression of hAAT into the medium was measured by ELISA. In vitro, the EF1 promoter construct resulted in 10-fold higher hAAT expression than the CMV promoter construct. In vivo transduction was performed by injecting doses of up to 1.4×10 13 Dnase-resistant particles of each vector into skeletal muscles of a number of different strains of mice (including C57B1/6, Balb/c, and SCID). In vivo, the CMV promoter construct resulted in higher levels of expression, with sustained serum levels up to 800 μg/ml in SCID mice, approximately 10,000- fold higher than those previously observed with proteins secreted from AAV vectors in muscle. At lower doses in both C57B1/6 and SCID mice, expression was delayed for several weeks, but was sustained for over 10 weeks without declining. Thus, increasing dosage AAV vector via transduction of skeletal muscle provides a means for replacing AAT or other serum proteins.

Transduction of muscle using the vectors of the subject invention presents several advantages in that it is stable, non-toxic, and relatively nonimmunogenic. Furthermore, certain transcription promoters, such as the CMV promoter, which appear to be markedly down-regulated in other contexts have been found to remain active over time as used in the subject invention. Using the materials and methods of the subject invention, microgram/ml serum levels of a therapeutic protein can be achieved. In an exemplified embodiment, the levels of in vivo protein expression achieved represent a 10,000-fold or more increase over previously published results. In addition, a dose-effect relationship was demonstrable within the range of doses used, providing for further increases in expression levels as vector dose is increased.

In another embodiment of the invention, recombinant AAV vectors i.e., C-AT, p43C-AT, P43CB-AT, E-AT and dE-AT comprising the human AAT gene (hAAT) were constructed and packaged using standard techniques. A murine liver cell line, HO15, was transfected with each vector and expression of hAAT into the medium was measured by ELISA. In vitro, transduction with the p43CB-AT vector exhibited the highest level of hAAT expression. In vivo, the p43CB-AT vector also gave higher levels of expression. Portal vein administration appeared to be the more efficient route of administration as mice injected in this manner exhibited higher levels of expression than those receiving peripheral vein injections. Transduction of liver offers the same advantages as for muscle, but hepatocytes may be more efficient at secretion of protein.

The dosage of recombinant vector or the virus to be administered to an animal in need of such treatment can be determined by the ordinarily skilled clinician based on various parameters such as mode of administration, duration of treatment, the disease state or condition involved, and the like. Typically, recombinant virus of the invention is administered in doses between 10 5 and 10 14 infectious units. The recombinant vectors and virus of the present invention can be prepared in formulations using methods and materials known in the art. Numerous formulations can be found in Remington's Pharmaceutical Sciences, 15 th Edition (1975).

All publications and patents cited herein are expressly incorporated by reference.

Materials and Methods

Construction of rAAV plasmids. The rAAV-AAT vector plasmids used for these experiments are depicted diagrammatically (FIG. 1 ). Briefly, the plasmid pN2FAT (Garver et al., 1987) was digested with XhoI to release 1.8-kb fragment containing the human AAT cDNA along with the SV40 promoter and a polyadenylation signal. This fragment was subcloned into a plasmid, pBlueScript (Stratagene) and, after the removal of the SV40 promoter by Hind III digestion and religation, the hAAT cDNA with its polyA signal was released by XbaI and XhoI digestion. This 1.4-kb XbaI-XhoI fragment was then cloned in to the pTR-UF5 (an AAV-inverted terminal repeat-containing vector) plasmid (Zolotukhin et al., 1996) between the XbaI site 3′ to the CMV promoter and the XhoI site 5′ to the polyoma virus enhancer/HSV thymidine kinase promoter cassette, which drives neo in that construct. This yielded the pAAV-CMV-AAT construct (C-AT). Analogous constructs using the promoter from the small nuclear RNA proteins, U1a and U1b, (to give the A-AT and B-AT constructs, respectively) and human elongation factor 1-alpha (EF1) promoter (to give the E-AT construct) were constructed by substituting each of these promoter cassettes in place of the CMV promoter, between the KpnI and XbaI sites.

The construct dE-AT was derived from E-AT by deletion of the silencer (52 bp) by SAC II-cut (Wakabayashi-Ito et al., 1994). C-AT2 is similar with C-AT except there are SV40 intron and poly (A) sequences flanking the cDNA of hAAT. The p43C-AT was constructed by insertion of hAAT cDNA to an AAV-vector plasmid (p43), which has CMV promoter, intron and poly (A) sequences. The p43CB-AT is derived by replacement of CMV promoter with CMV enhancer and chicken β-actin promoter sequences. The p43C-AT-IN is derived from p43C-AT by insertion of intron II sequences of hAAT gene to hAAT cDNA (Brantly et al., 1995).

Packaging of rAAV vectors. Vectors were packaged using a modification of the method described by Ferrari et al. (1997). Briefly, plasmids containing the AAV rep and cap genes (Li et al., 1997) and the Ad genes (E2a, E4 and VA-RNA) were co-transfected along with the appropriate AAV-AAT vector plasmid into 293 cells grown in Cell Factories (Nunc). Cells were harvested by trypsinization and disrupted by freeze-thaw lysis to release vector virions which were then purified by iodixanol gradient ultracentrifugation followed by heparin sepharose affinity column purification. Alternatively, recombinant virus can be prepared according to methods described in Zolotukhin et al. (1999).

Vector preparations had their physical titer assessed by quantitative competitive PCR and their biological titer assessed by infectious center assay. The presence of wild-type AAV was also assessed using these same assays with appropriate internal AAV probes. The high-dose C-AT stock had a particle-titer of 2.0×10 4 particles/ml and an infectious titer of 5.0×10 11 infectious units (i.u.)/ml (particle to i.u. ratio=400:1). The low-dose C-AT measured 8×10 12 particles/ml and 1.2×10 10 i.u./ml (particle to i.u.=667:1). For the E-AT experiments, the titers were 1×10 13 particles/ml and 2.5×10 10 i.u./ml (particle to i.u.=400:1). The low-dose C-AT stock had a wt-like AAV particle titer (i.e., positive AAV genome PCR) equal to 0.1 times the recombinant titer but no detectable infectious wtAAV. The other two preparations had wt-like AAV particle titers <10 −5 times the recombinant titer and no detectable infectious wtAAV.

In vitro transfection and transduction experiments. The C2C12 murine myoblast line was used for in vitro transfection and transduction experiments. Cells were grown in 35-mm wells with approximately 4×10 5 cells per well and transfected with 5 μg of each plasmid DNA using SUPERFECT (Qiagen Corp.). Secretion of hAAT into the medium was assessed at 2 days after transfection using an antigen-capture ELISA assay with standards (Brantly et al., 1991). An SV40 promoter luciferase-expression plasmid, pGL2 (Promega), was used as an internal control. For transduction experiments, cells were grown under similar conditions and were transduced with vector at multiplicities of infection ranging from 4×10 5 to 4×10 6 particles per cell. Cells were then passaged in the presence of geneticin sulfate (350 μg/ml) and geneticin-resistant clones were isolated for hAAT secretion studies.

In vivo injection of AAV-C-AT and AAV-E-AT vectors into murine muscle. Mice strains (C57B1/6, SCID, and Balb/c) were obtained from Jackson Laboratories (Bar Harbor, Me.) and were handled under specific pathogen-free conditions under a protocol approved by the University of Florida Institutional Animal Care and Use Committee. Animals were anesthetized by metaphane inhalation and aliquots of vector were injected percutaneously into the quadriceps femoris muscles of both hind limbs. The volume of vector ranged from 50 to 100 μl per injection site and the total amount of virus injected per animal ranged from 5×10 10 to 1.4×10 13 Dnase-resistant particles.

Antigen capture ELISA assay for hAAT expression. Microtiter plates (Immulon 4, Dynex Technologies, Chantilly, Va.) were coated with 100 μl of a 1:200 dilution of goat anti-human AAT (CAPPEL/ICN) in Vollers buffer (Na2CO3=2.76 g, NaHCO3=1.916 g, NaN3=0.2 g, d.H2O=1 liter, Adjust PH=9.6) overnight at 4° C. After washing, standards and unknown samples containing hAAT were incubated in the plates at 37° C. for 1 hour. After blocking in 3% BSA in PBS-Tween 20 at 37° C. for 1 hour, a second antibody (1:1000 dilution of rabbit anti-human AAT, Boehringer Mannheim) was reacted with the captured antigen at 37° C. for 1 hour. Detection was performned using a third antibody incubation (1:800 dilution of goat anti-rabbit IgG-peroxidase conjugate, 37° C.) followed by o-phenylenediamine (OPD, Sigma) detection and measurement of the absorbance at 490 nm.

ELISA assay for anti-hAAT and anti-AAV VP3 antibodies. Wells were coated with antigen (1 μg of hAAT or 100 ng of VP3) at 4° C. overnight, blocked with 3% BSA and then reacted with dilutions of either test serum or with positive control antibodies at 37° C. for 1 hour. After washing, a goat-anti-mouse IgG-peroxidase conjugate was used as a secondary antibody (1:1500 dilution) to detect bound anti-AAT antibody, using a standard OPD reaction, as described above. Antibody levels were quantitated by comparison with a standard curve generated by reacting dilutions of known positive monoclonal antibodies against VP3 and hAAT.

Lymphocyte proliferation assays to detect cell-mediated immune responses. Lymphocyte proliferation assays were performed in order to detect T cell responses to the hAAT and VP3 antigens. Freshly isolated splenocytes were grown in primary culture in 96 well plates coated with 0, 0.1, 1, and 10 μg of either hAAT or VP3 in RPMI-C+ medium. On day three, a pulse of 3 H-thymidine was added, and the cells were harvested on day 4 for lysis and scintillation counting. Phytohemagglutinin (PHA) was used as a mitogen for positive control wells. A stimulation index was calculated for each antigen dosage level by dividing the counts per minute (cpm) of 3 H-thymidine incorporated in the antigen-stimulated cells by the cpm in a control (unstimulated) well.

Following are examples which illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

EXAMPLE 1

In vitro Studies in Murine C2C12 Myoblasts

In order to determine the relative strength of a number of constitutively active promoters in the context of AAV-AAT vectors, packageable AAV-AAT expression vectors containing one of the CMV, EF1, U1a or U1b promoters ( FIG. 1 ) were constructed. Each of these constructs were transfected in to the murine C2C12 myoblast cell line. Both the EF1 and the CMV promoter were active for AAT expression, with EF1 construct (AAV-E-AT) expressing 850 ng/10 5 cells/day and the CMV construct (AAV-C-AT) expressing approximately 670 ng/10 5 cells/day, as measured by a human-specific ELISA assay for AAT (FIG. 2 ). This difference was not statistically significant. The levels of expression from the U1a and U1b constructs were undetectable.

In order to better characterize the level and duration of expression in the setting of vector transduction, cultures of C2C12 cells were transduced with either AAV-E-AT or AAV-C-AT at multiplicities of infection ranging from 4×10 5 to 4×10 6 Dnase-resistant particles per cell. Cells were then selected for expression of the neo gene (present in each of the AAV constructs) by growth in G418-containing medium. Several cell clones and pooled cell populations were independently analyzed for AAT expression at four weeks post-transduction (FIG. 3 ). There was a clear trend toward higher levels of expression at higher multiplicities of infection, and the E-AT construct expressed at least 10-fold greater quantities under all conditions in these long-term cultures. The most active E-AT clone expressed hAAT at a rate of over 1400 ng/10 5 cells/day.

EXAMPLE 2

In vivo Expression of hAAT from Murine Skeletal Muscle

In order to determine whether the AAV-AAT constructs would be active in vivo in skeletal muscle, doses of vector were injected into the quadriceps femoris muscle of mice. Circulating serum levels of hAAT were then measured for 11 to 15 weeks after the initial injection. Four saline-injected animals from each mouse strain served as controls. In the case of the C-AT vector (FIG. 5 A), levels of expression were sufficient to achieve serum levels in excess of 800 μg/ml in SCID mice after a single injection of 1.4×10 13 particles. A dose-effect relationship was observed, with expression levels in SCID being at least 20-fold lower at the 5×10 11 particle dose. The levels of expression increased over the first several weeks after injection and were stable thereafter until the time of sacrifice. Since hAAT has a half-life of less than 1 week, this indicated continuous expression. Levels from C57B1/6 mice were comparable, and also achieved values close to the therapeutic range. In similar studies, two of three Balb/c mice injected with 1×10 11 particles of the C-AT vector did not express hAAT at detectable levels. Both of these were found to have developed high levels of anti-hAAT antibodies.

Surprisingly, expression levels from the AAV-E-AT vector after in vivo injection were modestly lower than those seen with the C-AT vector (FIG. 5 B), with maximal levels of approximately 250 ng/ml at the 5×10 11 dose at and beyond 7 weeks in SCID mice. When the dose was further increased to 1×10 12 particles, levels of approximately 1200 ng/ml were observed. These levels were stable for one year post-injection (FIG. 5 C). Levels observed in SCID and immune competent C57B1/6 mice were similar.

EXAMPLE 3

Immunologic Studies

In studies in Balb/c mice, antibody levels against hAAT were high in 2 of 3 animals injected. The one which did not have circulating anti-hAAT was the only animal with levels of hAAT expression similar to those in the C57B1/6 and SCID groups. The high-dose C57-C-AT injection group had detectable levels of antibody directed against VP3, but not hAAT.

In order to determine whether any cell-mediated immune responses were mounted, lymphocyte proliferation assays were performed using either hAAT or AAV-VP3 for antigenic stimulation of primary splenic lymphocytes harvested at the time of animal sacrifice, 16 weeks post-vector injection. Using this method, no immune responses were detectable in any of the mice.

EXAMPLE 4

Lack of Toxicity from Direct Vector Injection

In order to determine whether there was any direct toxicity, inflammation, or neoplastic change associated with vector injection, animals underwent complete necropsies. Histopathologic examination was performed on 5 μm sections taken from the site of vector injection and from a panel of other organs, including the brain, heart, lungs, trachea, pancreas, spleen, liver, kidney, and jejunum. No histologic abnornalities were observed in any of these sites, even among those mice which developed humoral immune responses against hAAT.

EXAMPLE 5

Molecular Evidence of AAV-AAT Vector Persistence

To confirm the presence of vector DNA, a vector-specific PCR (neo primers 5′-TATGGGATCGGCCATTGAAC-3′ (SEQ ID NO:12), and 5′-CCTGATGCTCTTC-GTCCAGA-3′ (SEQ ID NO: 13), was performed on DNA extracted from 3 SCID mice 16 weeks after injection with the C-AT vector, and PCR products were analyzed by Southern blot analysis with a 32 P-labeled vector-specific probe (FIG. 8 ). The state of vector DNA was analyzed using the Hirt procedure (Carter et al, 1983) to separate the low molecular weight episomal DNA from the high molecular weight fraction, which would contain integrated forms and large concatemers. In each case, vector DNA was present in the high molecular weight DNA fraction, whereas in only one of the animals was there a signal in the episomal fraction. This result indicates that by 16 weeks most of the vector DNA in our animals was either integrated or in large concatemers.

EXAMPLE 6

In vivo Expression of hAAT from Murine Liver

Portal vein or tail vein injections were performed on 18 female C57BL/6 mice 8-10 weeks of age. The injection volume was 100 μl per mouse.

Each group had the following parameters:

1. Group 1: 100 μl of PBS n=4.

2. Group 2: 100 μl of p43CB-AT (3×10 10 IU/animal) n=3.

3. Group 3: 100 μl of p43CB-AT (4×10 9 IU/animal) n=4.

4. Group 4: 100 μl of C-AT (4×10 9 IU/animal) n=2.

5. Group 5: 100 μl of E-AT (4×10 9 IU/animal) n=4.

6. Group 6: EATM TV=100 μl by tail vein injection of E-AT (4×10 9 IU/animal) n=3.

7. Group 0: 100 μl of PBS by tail vein injection n=2. A total of 22 animals were used in this study.

All animals were anesthetized with 2-2-2 tribromoethanol (Avertin) using a working solution of 20 mg/ml at a dosage of 0.5 mg/g IP. A 2 cm ventral midline abdominal incision was made from the pubic symphysis extending cranially to the xyphoid process through skin and muscle layers. The portal vein was exposed by retracting the intestines and associated mesentery to the left side of the animal. Additionally, the quadrate and right medial lobes of the liver were retracted cranially. Intestines and peritoneal cavity were continuously lavaged with 0.9% NaCl.

Virus or PBS was delivered into the portal vein using a 30 g needle attached to a 100 ul capillary pipette using mouth delivery via rubber tubing and a Drummond self-locking double layer 0.8 um filter. A small piece of Gel-Foam (0.5×0.5 cm) was applied to the injection site before the needle was removed from the portal vein. The needle was retracted from beneath the Gel-Foam and the piece was held in place with forceps while the intestines were replaced into the peritoneal cavity.

The muscle and skin were closed in one layer using 2 simple interrupted 3-0 nylon sutures on an FS-1 cutting needle. Surgeries were performed on a thermoregulated operating board designed to maintain a temperature of 37 degrees. For recovery from anesthesia, the animals were placed under a heat lamp adjusted to maintain an ambient temperature of approximately 37 degrees and given subcutaneous fluid if there was a significant amount of blood loss during surgery.

Serum levels of hAAT in the mice were measured two weeks after injection. Serum levels of about 200-150 μg/ml hAAT were detected in mice receiving the p43CB-AT vector (FIG. 13 ). Studies using the E-AT vector show that injection of vector by portal vein led to greater levels of hAAT secretion as compared to E-AT administered by tail vein injection.

EXAMPLE 7

In vivo expression of hAAT from murine lung

Mice were injected intratracheally with either C-AT or p43CB-AT vector. Serum levels of hAAT in the mice were measured at day 3, 14 and 31 after injection (FIG. 14 ). The p43CB-AT vector mediated high levels of expression of hAAT in lung.

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

REFERENCES

U.S. Pat. No. 5,399,346

U.S. Pat. No. 5,439,824

U.S. Pat. No. 5,658,785

U.S. Pat. No. 5,858,351

Afione, S. A., Conrad, C. K., Kearns, W. G., Chunduru, S., Adams, R., Reynolds, T. C., Guggino, W. B., Cutting, G. R., Carter, B. J. and Flotte, T. R. (1996) J. Virol. 70:3235-3241.

Brantly, M. L., Wittes, J. T., Vogelmeier, C. F., Hubbard, R. C., Fells, G. A., Crystal, R. G. (1991) Chest 100:703-708.

Briggs, M. R., Kadonga, J. T., Bell, S. P., Tjian, R. (1986) Science 234:47-52.

Carter et al. (1983) Virology 126:505-515.

Deshpande, N., Chopra, A., Rangarajan, A., Shashidhara, L. S., Rodrigues, V., Krishna, S. (1997) J. Biol. Chem 272(16):10664-10668.

Garver, R. I., Jr., Chytil, A., Courtney, M., Crystal, R. G. (1987) Science 237:762-764.

Ferrari, F. K., Samulski, T., Shenk, T., Samulski, R. J. (1996) J. Virol. 70:3227-3234.

Ferrari, F. K., Xiao, X., McCarty, D. M., Samulski, R. J. (1997) Nature Med 3:1295-97.

Fisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., Wilson, J. M. (1996) J. Virol. 70:520-532.

Flotte, T. R., Afione, S. A., Conrad, C., McGrath, S. A., Solow, R., Oka, H., Zeitlin, P. L., Guggino, W. B., Carter, B. J. (1993) Proc. Natl. Acad. Sci. USA 90:10613-10617.

Jooss, K., Yang, Y., Fisher, K. J., Wilson, J. M. (1998) J. Virol. 72:4212-4223.

Li, X, Eastman, E. M., Schwartz, R. J., Draghia-Akli, R. (1999) Nat. Biotechnol 17(3):241-245.

Li et al. (1997) J. Virol. 71:5236-43.

Kearns, W. G., Afione, S. A., Fulmer, S. B., Caruso, J., Flotte, T. R., Cutting, G. R. (1996) Gene Ther. 3:748-755.

Kessler, P. D., Podsakoff, G., Chen, X., McQuiston, S. A., Colosim, P. C., Matelis, L. A., Kurtzman, G. and Byrne, B. J. (1996) Proc. Natl. Acad. Sci. USA 93:14082-14087.

Klein, R. L. et al. (1998) Exp. Neurol. 150:183-194.

Kotin, R. M., Siniscalco, M., Samulski, R. J., Zhu, X. D., Hunter, L., Laughlin, C. A., McLaughlin, S., Muzyczka, N., Rocchi, M., Berns, K. I. (1990) Proc. Natl. Acad. Sci. USA 87:2211-2215.

Mitchell, P. J., Tjian, R. (1989) Science 245:371-378.

Murphy, J. E., Zhou, S., Giese, K., Williams, L. T., Escobedo, J. A., Dwarki, V. J. (1997) Proc. Natl. Acad. Sci. USA 94:13921-13926, 1997.

Nettelbeck, D. M., Jerome V., Muller R. (1998) Gene Ther 5(12)1656-1664.

Pitluk, Z. W., Ward, D. C. (1991) J. Virol. 65:6661-6670.

Stewart, A. F., Richard, III, C. W., Suzow, J., Stephan D., Weremowicz, S., Morton, C. C., Andra, C. N. (1996) Genomics 37(1):68-76.

Wei, C-F. et al (1993) J. Biol Chem 258(22):13506-13512.

Xiao, X., Li, J., Samulski, R. J. (1996) J. Virol. 70:8098-8108.

Zolotukhin, S., Potter, M., Hauswirth, W., Guy, J., Muzyczka, N. (1996) J. Virol. 70(7):4646-4654.

Zolotukhin, S. et al. (1999) Gene Ther. (6).

13 1 6565 DNA Artificial Sequence Description of Artificial SequencePLASMID C-AT 1gggggggggg ggggggggtt ggccactccc tctctgcgcg ctcgctcgct cactgaggcc 60gggcgaccaa aggtcgcccg acgcccgggc tttgcccggg cggcctcagt gagcgagcga 120gcgcgcagag agggagtggc caactccatc actaggggtt cctagatctg aattcggtac 180ccgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac ccccgcccat 240tgacgtcaat aatgacgtat gttcccatag taacgccaat agggactttc cattgacgtc 300aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc 360caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt 420acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta 480ccatggtgat gcggttttgg cagtacatca atgggcgtgg atagcggttt gactcacggg 540gatttccaag tctccacccc attgacgtca atgggagttt gttttggcac caaaatcaac 600gggactttcc aaaatgtcgt aacaactccg ccccattgac gcaaatgggc ggtaggcgtg 660tacggtggga ggtctatata agcagagctc gtttagtgaa ccgtcagatc gcctggagac 720gccatccacg ctgttttgac ctccatagaa gacaccggga ccgatccagc ctccggactc 780tagaactagt ggatcccccg ggctgcagga attcgatatc aagcttgggg attttcaggc 840accaccactg acctgggaca gtgaatcgac aatgccgtct tctgtctcgt ggggcatcct 900cctgctggca ggcctgtgct gcctggtccc tgtctccctg gctgaggatc cccagggaga 960tgctgcccag aagacagata catcccacca tgatcaggat cacccaacct tcaacaagat 1020cacccccaac ctggctgagt tcgccttcag cctataccgc cagctggcac accagtccaa 1080cagcaccaat atcttcttct ccccagtgag catcgctaca gcctttgcaa tgctctccct 1140ggggaccaag gctgacactc acgatgaaat cctggagggc ctgaatttca acctcacgga 1200gattccggag gctcagatcc atgaaggctt ccaggaactc ctccgtaccc tcaaccagcc 1260agacagccag ctccagctga ccaccggcaa tggcctgttc ctcagcgagg gcctgaagct 1320agtggataag tttttggagg atgttaaaaa gttgtaccac tcagaagcct tcactgtcaa 1380cttcggggac accgaagagg ccaagaaaca gatcaacgat tacgtggaga agggtactca 1440agggaaaatt gtggatttgg tcaaggagct tgacagagac acagtttttg ctctggtgaa 1500ttacatcttc tttaaaggca aatgggagag accctttgaa gtcaaggaca ccgaggaaga 1560ggacttccac gtggaccagg tgaccaccgt gaaggtgcct atgatgaagc gtttaggcat 1620gtttaacatc cagcactgta agaagctgtc cagctgggtg ctgctgatga aatacctggg 1680caatgccacc gccatcttct tcctgcctga tgaggggaaa ctacagcacc tggaaaatga 1740actcacccac gatatcatca ccaagttcct ggaaaatgaa gacagaaggt ctgccagctt 1800acatttaccc aaactgtcca ttactggaac ctatgatctg aagagcgtcc tgggtcaact 1860gggcatcact aaggtcttca gcaatggggc tgacctctcc ggggtcacag aggaggcacc 1920cctgaagctc tccaaggccg tgcataaggc tgtgctgacc atcgacgaga aagggactga 1980agctgctggg gccatgtttt tagaggccat acccatgtct atcccccccg aggtcaagtt 2040caacaaaccc tttgtcttct taatgattga acaaaatacc aagtctcccc tcttcatggg 2100aaaagtggtg aatcccaccc aaaaataact gcctctcgct cctcaacccc tcccctccat 2160ccctggcccc ctccctggat gacattaaag aagggttgag ctggtaaccc cccccccccc 2220tgcaggggcc ctcgagcagt gtggttttgc aagaggaagc aaaaagcctc tccacccagg 2280cctggaatgt ttccacccaa gtcgaaggca gtgtggtttt gcaagaggaa gcaaaaagcc 2340tctccaccca ggcctggaat gtttccaccc aatgtcgagc aaccccgccc agcgtcttgt 2400cattggcgaa ttcgaacacg cagatgcagt cggggcggcg cggtcccagg tccacttcgc 2460atattaaggt gacgcgtgtg gcctcgaaca ccgagcgacc ctgcagccaa tatgggatcg 2520gccattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 2580ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 2640gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 2700caggacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 2760ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 2820gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 2880cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 2940atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 3000gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgcg catgcccgac 3060ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 3120ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 3180atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 3240ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 3300gacgagttct tctgagggga tccgtcgact agagctcgct gatcagcctc gactgtgcct 3360tctagttgcc agccatctgt tgtttgcccc tcccccgtgc cttccttgac cctggaaggt 3420gccactccca ctgtcctttc ctaataaaat gaggaaattg catcgcattg tctgagtagg 3480tgtcattcta ttctgggggg tggggtgggg caggacagca agggggagga ttgggaagac 3540aatagcaggc atgctgggga gagatctagg aacccctagt gatggagttg gccactccct 3600ctctgcgcgc tcgctcgctc actgaggccg cccgggcaaa gcccgggcgt cgggcgacct 3660ttggtcgccc ggcctcagtg agcgagcgag cgcgcagaga gggagtggcc aacccccccc 3720cccccccccc tgcagccctg cattaatgaa tcggccaacg cgcggggaga ggcggtttgc 3780gtattgggcg ctcttccgct tcctcgctca ctgactcgct gcgctcggtc gttcggctgc 3840ggcgagcggt atcagctcac tcaaaggcgg taatacggtt atccacagaa tcaggggata 3900acgcaggaaa gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg 3960cgttgctggc gtttttccat aggctccgcc cccctgacga gcatcacaaa aatcgacgct 4020caagtcagag gtggcgaaac ccgacaggac tataaagata ccaggcgttt ccccctggaa 4080gctccctcgt gcgctctcct gttccgaccc tgccgcttac cggatacctg tccgcctttc 4140tcccttcggg aagcgtggcg ctttctcaat gctcacgctg taggtatctc agttcggtgt 4200aggtcgttcg ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg 4260ccttatccgg taactatcgt cttgagtcca acccggtaag acacgactta tcgccactgg 4320cagcagccac tggtaacagg attagcagag cgaggtatgt aggcggtgct acagagttct 4380tgaagtggtg gcctaactac ggctacacta gaaggacagt atttggtatc tgcgctctgc 4440tgaagccagt taccttcgga aaaagagttg gtagctcttg atccggcaaa caaaccaccg 4500ctggtagcgg tggttttttt gtttgcaagc agcagattac gcgcagaaaa aaaggatctc 4560aagaagatcc tttgatcttt tctacggggt ctgacgctca gtggaacgaa aactcacgtt 4620aagggatttt ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa 4680aatgaagttt taaatcaatc taaagtatat atgagtaaac ttggtctgac agttaccaat 4740gcttaatcag tgaggcacct atctcagcga tctgtctatt tcgttcatcc atagttgcct 4800gactccccgt cgtgtagata actacgatac gggagggctt accatctggc cccagtgctg 4860caatgatacc gcgagaccca cgctcaccgg ctccagattt atcagcaata aaccagccag 4920ccggaagggc cgagcgcaga agtggtcctg caactttatc cgcctccatc cagtctatta 4980attgttgccg ggaagctaga gtaagtagtt cgccagttaa tagtttgcgc aacgttgttg 5040ccattgctac aggcatcgtg gtgtcacgct cgtcgtttgg tatggcttca ttcagctccg 5100gttcccaacg atcaaggcga gttacatgat cccccatgtt gtgcaaaaaa gcggttagct 5160ccttcggtcc tccgatcgtt gtcagaagta agttggccgc agtgttatca ctcatggtta 5220tggcagcact gcataattct cttactgtca tgccatccgt aagatgcttt tctgtgactg 5280gtgagtactc aaccaagtca ttctgagaat agtgtatgcg gcgaccgagt tgctcttgcc 5340cggcgtcaat acgggataat accgcgccac atagcagaac tttaaaagtg ctcatcattg 5400gaaaacgttc ttcggggcga aaactctcaa ggatcttacc gctgttgaga tccagttcga 5460tgtaacccac tcgtgcaccc aactgatctt cagcatcttt tactttcacc agcgtttctg 5520ggtgagcaaa aacaggaagg caaaatgccg caaaaaaggg aataagggcg acacggaaat 5580gttgaatact catactcttc ctttttcaat attattgaag catttatcag ggttattgtc 5640tcatgagcgg atacatattt gaatgtattt agaaaaataa acaaataggg gttccgcgca 5700catttccccg aaaagtgcca cctgacgtct aagaaaccat tattatcatg acattaacct 5760ataaaaatag gcgtatcacg aggccctttc gtctcgcgcg tttcggtgat gacggtgaaa 5820acctctgaca catgcagctc ccggagacgg tcacagcttg tctgtaagcg gatgccggga 5880gcagacaagc ccgtcagggc gcgtcagcgg gtgttggcgg gtgtcggggc tggcttaact 5940atgcggcatc agagcagatt gtactgagag tgcaccatat gcggtgtgaa ataccgcaca 6000gatgcgtaag gagaaaatac cgcatcagga aattgtaaac gttaatattt tgttaaaatt 6060cgcgttaaat ttttgttaaa tcagctcatt ttttaaccaa taggccgaaa tcggcaaaat 6120cccttataaa tcaaaagaat agaccgagat agggttgagt gttgttccag tttggaacaa 6180gagtccacta ttaaagaacg tggactccaa cgtcaaaggg cgaaaaaccg tctatcaggg 6240cgatggccca ctacgtgaac catcacccta atcaagtttt ttggggtcga ggtgccgtaa 6300agcactaaat cggaacccta aagggagccc ccgatttaga gcttgacggg gaaagccggc 6360gaacgtggcg agaaaggaag ggaagaaagc gaaaggagcg ggcgctaggg cgctggcaag 6420tgtagcggtc acgctgcgcg taaccaccac acccgccgcg cttaatgcgc cgctacaggg 6480cgcgtcgcgc cattcgccat tcaggctacg caactgttgg gaagggcgat cggtgcgggc 6540ctcttcgcta ttacgccagg ctgca 6565 2 7405 DNA Artificial Sequence Description of Artificial SequencePLASMID E-AT 2gggggggggg ggggggggtt ggccactccc tctctgcgcg ctcgctcgct cactgaggcc 60gggcgaccaa aggtcgcccg acgcccgggc tttgcccggg cggcctcagt gagcgagcga 120gcgcgcagag agggagtggc caactccatc actaggggtt cctagatctg aattcggtac 180cttggagcta agccagcaat ggtagaggga agattctgca cgtcccttcc aggcggcctc 240cccgtcacca ccccccccaa cccgccccga ccggagctga gagtaattca tacaaaagga 300ctcgcccctg ccttggggaa tcccagggac cgtcgttaaa ctcccactaa cgtagaaccc 360agagatcgct gcgttcccgc cccctcaccc gcccgctctc gtcatcactg aggtggagaa 420gagcatgcgt gaggctccgg tgcccgtcag tgggcagagc gcacatcgcc cacagtcccc 480gagaagttgg ggggaggggt cggcaattga accggtgcct agagaaggtg gcgcggggta 540aactgggaaa gtgatgtcgt gtactggctc cgcctttttc ccgagggtgg gggagaaccg 600tatataagtg cagtagtcgc cgtgaacgtt ctttttcgca acgggtttgc cgccagaaca 660caggtaagtg ccgtgtgtgg ttcccgcggg cctggcctct ttacgggtta tggcccttgc 720gtgccttgaa ttacttccac gcccctggct gcagtacgtg attcttgatc ccgagcttcg 780ggttggaagt gggtgggaga gttcgaggcc ttgcgcttaa ggagcccctt cgcctcgtgc 840ttgagttgag gcctggcctg ggcgctgggg ccgccgcgtg cgaatctggt ggcaccttcg 900cgcctgtctc gctgctttcg ataagtctct agccatttaa aatttttgat gacctgctgc 960gacgcttttt ttctggcaag atagtcttgt aaatgcgggc caagatctgc acactggtat 1020ttcggttttt ggggccgcgg gcggcgacgg ggcccgtgcg tcccagcgca catgttcggc 1080gaggcggggc ctgcgagcgc ggccaccgag aatcggacgg gggtagtctc aagctggccg 1140gcctgctctg gtgcctggcc tcgcgccgcc gtgtatcgcc ccgccctggg cggcaaggct 1200ggcccggtcg gcaccagttg cgtgagcgga aagatggccg cttcccggcc ctgctgcagg 1260gagctcaaaa tggaggacgc ggcgctcggg agagcgggcg ggtgagtcac ccacacaaag 1320gaaaagggcc tttccgtcct cagccgtcgc ttcatgtgac tccacggagt accgggcgcc 1380gtccaggcac ctcgattagt tctcgagctt ttggagtacg tcgtctttag gttgggggga 1440ggggttttat gcgatggagt ttccccacac tgagtgggtg gagactgaag ttaggccagc 1500ttggcacttg atgtaattct ccttggaatt tgcccttttt gagtttggat cttggttcat 1560tctcaagcct cagacagtgg ttcaaagttt ttttcttcca tttcaggtgt cgtgaaaatc 1620tagaactagt ggatcccccg ggctgcagga attcgatatc aagcttgggg attttcaggc 1680accaccactg acctgggaca gtgaatcgac aatgccgtct tctgtctcgt ggggcatcct 1740cctgctggca ggcctgtgct gcctggtccc tgtctccctg gctgaggatc cccagggaga 1800tgctgcccag aagacagata catcccacca tgatcaggat cacccaacct tcaacaagat 1860cacccccaac ctggctgagt tcgccttcag cctataccgc cagctggcac accagtccaa 1920cagcaccaat atcttcttct ccccagtgag catcgctaca gcctttgcaa tgctctccct 1980ggggaccaag gctgacactc acgatgaaat cctggagggc ctgaatttca acctcacgga 2040gattccggag gctcagatcc atgaaggctt ccaggaactc ctccgtaccc tcaaccagcc 2100agacagccag ctccagctga ccaccggcaa tggcctgttc ctcagcgagg gcctgaagct 2160agtggataag tttttggagg atgttaaaaa gttgtaccac tcagaagcct tcactgtcaa 2220cttcggggac accgaagagg ccaagaaaca gatcaacgat tacgtggaga agggtactca 2280agggaaaatt gtggatttgg tcaaggagct tgacagagac acagtttttg ctctggtgaa 2340ttacatcttc tttaaaggca aatgggagag accctttgaa gtcaaggaca ccgaggaaga 2400ggacttccac gtggaccagg tgaccaccgt gaaggtgcct atgatgaagc gtttaggcat 2460gtttaacatc cagcactgta agaagctgtc cagctgggtg ctgctgatga aatacctggg 2520caatgccacc gccatcttct tcctgcctga tgaggggaaa ctacagcacc tggaaaatga 2580actcacccac gatatcatca ccaagttcct ggaaaatgaa gacagaaggt ctgccagctt 2640acatttaccc aaactgtcca ttactggaac ctatgatctg aagagcgtcc tgggtcaact 2700gggcatcact aaggtcttca gcaatggggc tgacctctcc ggggtcacag aggaggcacc 2760cctgaagctc tccaaggccg tgcataaggc tgtgctgacc atcgacgaga aagggactga 2820agctgctggg gccatgtttt tagaggccat acccatgtct atcccccccg aggtcaagtt 2880caacaaaccc tttgtcttct taatgattga acaaaatacc aagtctcccc tcttcatggg 2940aaaagtggtg aatcccaccc aaaaataact gcctctcgct cctcaacccc tcccctccat 3000ccctggcccc ctccctggat gacattaaag aagggttgag ctggtaaccc cccccccccc 3060tgcaggggcc ctcgagcagt gtggttttgc aagaggaagc aaaaagcctc tccacccagg 3120cctggaatgt ttccacccaa gtcgaaggca gtgtggtttt gcaagaggaa gcaaaaagcc 3180tctccaccca ggcctggaat gtttccaccc aatgtcgagc aaccccgccc agcgtcttgt 3240cattggcgaa ttcgaacacg cagatgcagt cggggcggcg cggtcccagg tccacttcgc 3300atattaaggt gacgcgtgtg gcctcgaaca ccgagcgacc ctgcagccaa tatgggatcg 3360gccattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 3420ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 3480gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 3540caggacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 3600ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 3660gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 3720cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 3780atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 3840gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgcg catgcccgac 3900ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 3960ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 4020atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 4080ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 4140gacgagttct tctgagggga tccgtcgact agagctcgct gatcagcctc gactgtgcct 4200tctagttgcc agccatctgt tgtttgcccc tcccccgtgc cttccttgac cctggaaggt 4260gccactccca ctgtcctttc ctaataaaat gaggaaattg catcgcattg tctgagtagg 4320tgtcattcta ttctgggggg tggggtgggg caggacagca agggggagga ttgggaagac 4380aatagcaggc atgctgggga gagatctagg aacccctagt gatggagttg gccactccct 4440ctctgcgcgc tcgctcgctc actgaggccg cccgggcaaa gcccgggcgt cgggcgacct 4500ttggtcgccc ggcctcagtg agcgagcgag cgcgcagaga gggagtggcc aacccccccc 4560cccccccccc tgcagccctg cattaatgaa tcggccaacg cgcggggaga ggcggtttgc 4620gtattgggcg ctcttccgct tcctcgctca ctgactcgct gcgctcggtc gttcggctgc 4680ggcgagcggt atcagctcac tcaaaggcgg taatacggtt atccacagaa tcaggggata 4740acgcaggaaa gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg 4800cgttgctggc gtttttccat aggctccgcc cccctgacga gcatcacaaa aatcgacgct 4860caagtcagag gtggcgaaac ccgacaggac tataaagata ccaggcgttt ccccctggaa 4920gctccctcgt gcgctctcct gttccgaccc tgccgcttac cggatacctg tccgcctttc 4980tcccttcggg aagcgtggcg ctttctcaat gctcacgctg taggtatctc agttcggtgt 5040aggtcgttcg ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg 5100ccttatccgg taactatcgt cttgagtcca acccggtaag acacgactta tcgccactgg 5160cagcagccac tggtaacagg attagcagag cgaggtatgt aggcggtgct acagagttct 5220tgaagtggtg gcctaactac ggctacacta gaaggacagt atttggtatc tgcgctctgc 5280tgaagccagt taccttcgga aaaagagttg gtagctcttg atccggcaaa caaaccaccg 5340ctggtagcgg tggttttttt gtttgcaagc agcagattac gcgcagaaaa aaaggatctc 5400aagaagatcc tttgatcttt tctacggggt ctgacgctca gtggaacgaa aactcacgtt 5460aagggatttt ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa 5520aatgaagttt taaatcaatc taaagtatat atgagtaaac ttggtctgac agttaccaat 5580gcttaatcag tgaggcacct atctcagcga tctgtctatt tcgttcatcc atagttgcct 5640gactccccgt cgtgtagata actacgatac gggagggctt accatctggc cccagtgctg 5700caatgatacc gcgagaccca cgctcaccgg ctccagattt atcagcaata aaccagccag 5760ccggaagggc cgagcgcaga agtggtcctg caactttatc cgcctccatc cagtctatta 5820attgttgccg ggaagctaga gtaagtagtt cgccagttaa tagtttgcgc aacgttgttg 5880ccattgctac aggcatcgtg gtgtcacgct cgtcgtttgg tatggcttca ttcagctccg 5940gttcccaacg atcaaggcga gttacatgat cccccatgtt gtgcaaaaaa gcggttagct 6000ccttcggtcc tccgatcgtt gtcagaagta agttggccgc agtgttatca ctcatggtta 6060tggcagcact gcataattct cttactgtca tgccatccgt aagatgcttt tctgtgactg 6120gtgagtactc aaccaagtca ttctgagaat agtgtatgcg gcgaccgagt tgctcttgcc 6180cggcgtcaat acgggataat accgcgccac atagcagaac tttaaaagtg ctcatcattg 6240gaaaacgttc ttcggggcga aaactctcaa ggatcttacc gctgttgaga tccagttcga 6300tgtaacccac tcgtgcaccc aactgatctt cagcatcttt tactttcacc agcgtttctg 6360ggtgagcaaa aacaggaagg caaaatgccg caaaaaaggg aataagggcg acacggaaat 6420gttgaatact catactcttc ctttttcaat attattgaag catttatcag ggttattgtc 6480tcatgagcgg atacatattt gaatgtattt agaaaaataa acaaataggg gttccgcgca 6540catttccccg aaaagtgcca cctgacgtct aagaaaccat tattatcatg acattaacct 6600ataaaaatag gcgtatcacg aggccctttc gtctcgcgcg tttcggtgat gacggtgaaa 6660acctctgaca catgcagctc ccggagacgg tcacagcttg tctgtaagcg gatgccggga 6720gcagacaagc ccgtcagggc gcgtcagcgg gtgttggcgg gtgtcggggc tggcttaact 6780atgcggcatc agagcagatt gtactgagag tgcaccatat gcggtgtgaa ataccgcaca 6840gatgcgtaag gagaaaatac cgcatcagga aattgtaaac gttaatattt tgttaaaatt 6900cgcgttaaat ttttgttaaa tcagctcatt ttttaaccaa taggccgaaa tcggcaaaat 6960cccttataaa tcaaaagaat agaccgagat agggttgagt gttgttccag tttggaacaa 7020gagtccacta ttaaagaacg tggactccaa cgtcaaaggg cgaaaaaccg tctatcaggg 7080cgatggccca ctacgtgaac catcacccta atcaagtttt ttggggtcga ggtgccgtaa 7140agcactaaat cggaacccta aagggagccc ccgatttaga gcttgacggg gaaagccggc 7200gaacgtggcg agaaaggaag ggaagaaagc gaaaggagcg ggcgctaggg cgctggcaag 7260tgtagcggtc acgctgcgcg taaccaccac acccgccgcg cttaatgcgc cgctacaggg 7320cgcgtcgcgc cattcgccat tcaggctacg caactgttgg gaagggcgat cggtgcgggc 7380ctcttcgcta ttacgccagg ctgca 7405 3 7054 DNA Artificial Sequence Description of Artificial SequencePLASMID dE-AT 3gggggggggg ggggggggtt ggccactccc tctctgcgcg ctcgctcgct cactgaggcc 60gggcgaccaa aggtcgcccg acgcccgggc tttgcccggg cggcctcagt gagcgagcga 120gcgcgcagag agggagtggc caactccatc actaggggtt cctagatctg aattcggtac 180cttggagcta agccagcaat ggtagaggga agattctgca cgtcccttcc aggcggcctc 240cccgtcacca ccccccccaa cccgccccga ccggagctga gagtaattca tacaaaagga 300ctcgcccctg ccttggggaa tcccagggac cgtcgttaaa ctcccactaa cgtagaaccc 360agagatcgct gcgttcccgc cccctcaccc gcccgctctc gtcatcactg aggtggagaa 420gagcatgcgt gaggctccgg tgcccgtcag tgggcagagc gcacatcgcc cacagtcccc 480gagaagttgg ggggaggggt cggcaattga accggtgcct agagaaggtg gcgcggggta 540aactgggaaa gtgatgtcgt gtactggctc cgcctttttc ccgagggtgg gggagaaccg 600tatataagtg cagtagtcgc cgtgaacgtt ctttttcgca acgggtttgc cgccagaaca 660caggtaagtg ccgtgtgtgg ttcccgcggg cggcgacggg gcccgtgcgt cccagcgcac 720atgttcggcg aggcggggcc tgcgagcgcg gccaccgaga atcggacggg ggtagtctca 780agctggccgg cctgctctgg tgcctggcct cgcgccgccg tgtatcgccc cgccctgggc 840ggcaaggctg gcccggtcgg caccagttgc gtgagcggaa agatggccgc ttcccggccc 900tgctgcaggg agctcaaaat ggaggacgcg gcgctcggga gagcgggcgg gtgagtcacc 960cacacaaagg aaaagggcct ttccgtcctc agccgtcgct tcatgtgact ccacggagta 1020ccgggcgccg tccaggcacc tcgattagtt ctcgagcttt tggagtacgt cgtctttagg 1080ttggggggag gggttttatg cgatggagtt tccccacact gagtgggtgg agactgaagt 1140taggccagct tggcacttga tgtaattctc cttggaattt gccctttttg agtttggatc 1200ttggttcatt ctcaagcctc agacagtggt tcaaagtttt tttcttccat ttcaggtgtc 1260gtgaaaatct agaactagtg gatcccccgg gctgcaggaa ttcgatatca agcttgggga 1320ttttcaggca ccaccactga cctgggacag tgaatcgaca atgccgtctt ctgtctcgtg 1380gggcatcctc ctgctggcag gcctgtgctg cctggtccct gtctccctgg ctgaggatcc 1440ccagggagat gctgcccaga agacagatac atcccaccat gatcaggatc acccaacctt 1500caacaagatc acccccaacc tggctgagtt cgccttcagc ctataccgcc agctggcaca 1560ccagtccaac agcaccaata tcttcttctc cccagtgagc atcgctacag cctttgcaat 1620gctctccctg gggaccaagg ctgacactca cgatgaaatc ctggagggcc tgaatttcaa 1680cctcacggag attccggagg ctcagatcca tgaaggcttc caggaactcc tccgtaccct 1740caaccagcca gacagccagc tccagctgac caccggcaat ggcctgttcc tcagcgaggg 1800cctgaagcta gtggataagt ttttggagga tgttaaaaag ttgtaccact cagaagcctt 1860cactgtcaac ttcggggaca ccgaagaggc caagaaacag atcaacgatt acgtggagaa 1920gggtactcaa gggaaaattg tggatttggt caaggagctt gacagagaca cagtttttgc 1980tctggtgaat tacatcttct ttaaaggcaa atgggagaga ccctttgaag tcaaggacac 2040cgaggaagag gacttccacg tggaccaggt gaccaccgtg aaggtgccta tgatgaagcg 2100tttaggcatg tttaacatcc agcactgtaa gaagctgtcc agctgggtgc tgctgatgaa 2160atacctgggc aatgccaccg ccatcttctt cctgcctgat gaggggaaac tacagcacct 2220ggaaaatgaa ctcacccacg atatcatcac caagttcctg gaaaatgaag acagaaggtc 2280tgccagctta catttaccca aactgtccat tactggaacc tatgatctga agagcgtcct 2340gggtcaactg ggcatcacta aggtcttcag caatggggct gacctctccg gggtcacaga 2400ggaggcaccc ctgaagctct ccaaggccgt gcataaggct gtgctgacca tcgacgagaa 2460agggactgaa gctgctgggg ccatgttttt agaggccata cccatgtcta tcccccccga 2520ggtcaagttc aacaaaccct ttgtcttctt aatgattgaa caaaatacca agtctcccct 2580cttcatggga aaagtggtga atcccaccca aaaataactg cctctcgctc ctcaacccct 2640cccctccatc cctggccccc tccctggatg acattaaaga agggttgagc tggtaacccc 2700ccccccccct gcaggggccc tcgagcagtg tggttttgca agaggaagca aaaagcctct 2760ccacccaggc ctggaatgtt tccacccaag tcgaaggcag tgtggttttg caagaggaag 2820caaaaagcct ctccacccag gcctggaatg tttccaccca atgtcgagca accccgccca 2880gcgtcttgtc attggcgaat tcgaacacgc agatgcagtc ggggcggcgc ggtcccaggt 2940ccacttcgca tattaaggtg acgcgtgtgg cctcgaacac cgagcgaccc tgcagccaat 3000atgggatcgg ccattgaaca agatggattg cacgcaggtt ctccggccgc ttgggtggag 3060aggctattcg gctatgactg ggcacaacag acaatcggct gctctgatgc cgccgtgttc 3120cggctgtcag cgcaggggcg cccggttctt tttgtcaaga ccgacctgtc cggtgccctg 3180aatgaactgc aggacgaggc agcgcggcta tcgtggctgg ccacgacggg cgttccttgc 3240gcagctgtgc tcgacgttgt cactgaagcg ggaagggact ggctgctatt gggcgaagtg 3300ccggggcagg atctcctgtc atctcacctt gctcctgccg agaaagtatc catcatggct 3360gatgcaatgc ggcggctgca tacgcttgat ccggctacct gcccattcga ccaccaagcg 3420aaacatcgca tcgagcgagc acgtactcgg atggaagccg gtcttgtcga tcaggatgat 3480ctggacgaag agcatcaggg gctcgcgcca gccgaactgt tcgccaggct caaggcgcgc 3540atgcccgacg gcgaggatct cgtcgtgacc catggcgatg cctgcttgcc gaatatcatg 3600gtggaaaatg gccgcttttc tggattcatc gactgtggcc ggctgggtgt ggcggaccgc 3660tatcaggaca tagcgttggc tacccgtgat attgctgaag agcttggcgg cgaatgggct 3720gaccgcttcc tcgtgcttta cggtatcgcc gctcccgatt cgcagcgcat cgccttctat 3780cgccttcttg acgagttctt ctgaggggat ccgtcgacta gagctcgctg atcagcctcg 3840actgtgcctt ctagttgcca gccatctgtt gtttgcccct cccccgtgcc ttccttgacc 3900ctggaaggtg ccactcccac tgtcctttcc taataaaatg aggaaattgc atcgcattgt 3960ctgagtaggt gtcattctat tctggggggt ggggtggggc aggacagcaa gggggaggat 4020tgggaagaca atagcaggca tgctggggag agatctagga acccctagtg atggagttgg 4080ccactccctc tctgcgcgct cgctcgctca ctgaggccgc ccgggcaaag cccgggcgtc 4140gggcgacctt tggtcgcccg gcctcagtga gcgagcgagc gcgcagagag ggagtggcca 4200accccccccc ccccccccct gcagccctgc attaatgaat cggccaacgc gcggggagag 4260gcggtttgcg tattgggcgc tcttccgctt cctcgctcac tgactcgctg cgctcggtcg 4320ttcggctgcg gcgagcggta tcagctcact caaaggcggt aatacggtta tccacagaat 4380caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta 4440aaaaggccgc gttgctggcg tttttccata ggctccgccc ccctgacgag catcacaaaa 4500atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac caggcgtttc 4560cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc ggatacctgt 4620ccgcctttct cccttcggga agcgtggcgc tttctcaatg ctcacgctgt aggtatctca 4680gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc gttcagcccg 4740accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga cacgacttat 4800cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta ggcggtgcta 4860cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta tttggtatct 4920gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac 4980aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg cgcagaaaaa 5040aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag tggaacgaaa 5100actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc tagatccttt 5160taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact tggtctgaca 5220gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt cgttcatcca 5280tagttgcctg actccccgtc gtgtagataa ctacgatacg ggagggctta ccatctggcc 5340ccagtgctgc aatgataccg cgagacccac gctcaccggc tccagattta tcagcaataa 5400accagccagc cggaagggcc gagcgcagaa gtggtcctgc aactttatcc gcctccatcc 5460agtctattaa ttgttgccgg gaagctagag taagtagttc gccagttaat agtttgcgca 5520acgttgttgc cattgctaca ggcatcgtgg tgtcacgctc gtcgtttggt atggcttcat 5580tcagctccgg ttcccaacga tcaaggcgag ttacatgatc ccccatgttg tgcaaaaaag 5640cggttagctc cttcggtcct ccgatcgttg tcagaagtaa gttggccgca gtgttatcac 5700tcatggttat ggcagcactg cataattctc ttactgtcat gccatccgta agatgctttt 5760ctgtgactgg tgagtactca accaagtcat tctgagaata gtgtatgcgg cgaccgagtt 5820gctcttgccc ggcgtcaata cgggataata ccgcgccaca tagcagaact ttaaaagtgc 5880tcatcattgg aaaacgttct tcggggcgaa aactctcaag gatcttaccg ctgttgagat 5940ccagttcgat gtaacccact cgtgcaccca actgatcttc agcatctttt actttcacca 6000gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaaggga ataagggcga 6060cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc atttatcagg 6120gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa caaatagggg 6180ttccgcgcac atttccccga aaagtgccac ctgacgtcta agaaaccatt attatcatga 6240cattaaccta taaaaatagg cgtatcacga ggccctttcg tctcgcgcgt ttcggtgatg 6300acggtgaaaa cctctgacac atgcagctcc cggagacggt cacagcttgt ctgtaagcgg 6360atgccgggag cagacaagcc cgtcagggcg cgtcagcggg tgttggcggg tgtcggggct 6420ggcttaacta tgcggcatca gagcagattg tactgagagt gcaccatatg cggtgtgaaa 6480taccgcacag atgcgtaagg agaaaatacc gcatcaggaa attgtaaacg ttaatatttt 6540gttaaaattc gcgttaaatt tttgttaaat cagctcattt tttaaccaat aggccgaaat 6600cggcaaaatc ccttataaat caaaagaata gaccgagata gggttgagtg ttgttccagt 6660ttggaacaag agtccactat taaagaacgt ggactccaac gtcaaagggc gaaaaaccgt 6720ctatcagggc gatggcccac tacgtgaacc atcaccctaa tcaagttttt tggggtcgag 6780gtgccgtaaa gcactaaatc ggaaccctaa agggagcccc cgatttagag cttgacgggg 6840aaagccggcg aacgtggcga gaaaggaagg gaagaaagcg aaaggagcgg gcgctagggc 6900gctggcaagt gtagcggtca cgctgcgcgt aaccaccaca cccgccgcgc ttaatgcgcc 6960gctacagggc gcgtcgcgcc attcgccatt caggctacgc aactgttggg aagggcgatc 7020ggtgcgggcc tcttcgctat tacgccaggc tgca 7054 4 5932 DNA Artificial Sequence Description of Artificial Sequencep43C-AT 4gggggggggg gggggggttg gccactccct ctctgcgcgc tcgctcgctc actgaggccg 60ggcgaccaaa ggtcgcccga cgcccgggct ttgcccgggc ggcctcagtg agcgagcgag 120cgcgcagaga gggagtggcc aactccatca ctaggggttc ctagatcttc aatattggcc 180attagccata ttattcattg gttatatagc ataaatcaat attggctatt ggccattgca 240tacgttgtat ctatatcata atatgtacat ttatattggc tcatgtccaa tatgaccgcc 300atgttggcat tgattattga ctagttatta atagtaatca attacggggt cattagttca 360tagcccatat atggagttcc gcgttacata acttacggta aatggcccgc ctggctgacc 420gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat 480agggactttc cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt 540acatcaagtg tatcatatgc caagtccgcc ccctattgac gtcaatgacg gtaaatggcc 600cgcctggcat tatgcccagt acatgacctt acgggacttt cctacttggc agtacatcta 660cgtattagtc atcgctatta ccatggtgat gcggttttgg cagtacacca atgggcgtgg 720atagcggttt gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt 780gttttggcac caaaatcaac gggactttcc aaaatgtcgt aataaccccg ccccgttgac 840gcaaatgggc ggtaggcgtg tacggtggga ggtctatata agcagagctc gtttagtgaa 900ccgtcagatc actagaagct ttattgcggt agtttatcac agttaaattg ctaacgcagt 960cagtgcttct gacacaacag tctcgaactt aagctgcaga agttggtcgt gaggcactgg 1020gcaggtaagt atcaaggtta caagacaggt ttaaggagac caatagaaac tgggcttgtc 1080gagacagaga agactcttgc gtttctgata ggcacctatt ggtcttactg acatccactt 1140tgcctttctc tccacaggtg tccactccca gttcaattac agctcttaag gctagagtac 1200ttaatacgac tcactatagg ctagaactag tggatccccc gggctgcagg aattcgatat 1260caagcttggg gattttcagg caccaccact gacctgggac agtgaatcga caatgccgtc 1320ttctgtctcg tggggcatcc tcctgctggc aggcctgtgc tgcctggtcc ctgtctccct 1380ggctgaggat ccccagggag atgctgccca gaagacagat acatcccacc atgatcagga 1440tcacccaacc ttcaacaaga tcacccccaa cctggctgag ttcgccttca gcctataccg 1500ccagctggca caccagtcca acagcaccaa tatcttcttc tccccagtga gcatcgctac 1560agcctttgca atgctctccc tggggaccaa ggctgacact cacgatgaaa tcctggaggg 1620cctgaatttc aacctcacgg agattccgga ggctcagatc catgaaggct tccaggaact 1680cctccgtacc ctcaaccagc cagacagcca gctccagctg accaccggca atggcctgtt 1740cctcagcgag ggcctgaagc tagtggataa gtttttggag gatgttaaaa agttgtacca 1800ctcagaagcc ttcactgtca acttcgggga caccgaagag gccaagaaac agatcaacga 1860ttacgtggag aagggtactc aagggaaaat tgtggatttg gtcaaggagc ttgacagaga 1920cacagttttt gctctggtga attacatctt ctttaaaggc aaatgggaga gaccctttga 1980agtcaaggac accgaggaag aggacttcca cgtggaccag gtgaccaccg tgaaggtgcc 2040tatgatgaag cgtttaggca tgtttaacat ccagcactgt aagaagctgt ccagctgggt 2100gctgctgatg aaatacctgg gcaatgccac cgccatcttc ttcctgcctg atgaggggaa 2160actacagcac ctggaaaatg aactcaccca cgatatcatc accaagttcc tggaaaatga 2220agacagaagg tctgccagct tacatttacc caaactgtcc attactggaa cctatgatct 2280gaagagcgtc ctgggtcaac tgggcatcac taaggtcttc agcaatgggg ctgacctctc 2340cggggtcaca gaggaggcac ccctgaagct ctccaaggcc gtgcataagg ctgtgctgac 2400catcgacgag aaagggactg aagctgctgg ggccatgttt ttagaggcca tacccatgtc 2460tatccccccc gaggtcaagt tcaacaaacc ctttgtcttc ttaatgattg aacaaaatac 2520caagtctccc ctcttcatgg gaaaagtggt gaatcccacc caaaaataac tgcctctcgc 2580tcctcaaccc ctcccctcca tccctggccc cctccctgga tgacattaaa gaagggttga 2640gctggtaacc cccccccccc ctgcaggggc cctcgacccg ggcggccgct tcgagcagac 2700atgataagat acattgatga gtttggacaa accacaacta gaatgcagtg aaaaaaatgc 2760tttatttgtg aaatttgtga tgctattgct ttatttgtaa ccattataag ctgcaataaa 2820caagttaaca acaacaattg cattcatttt atgtttcagg ttcaggggga gatgtgggag 2880gttttttaaa gcaagtaaaa cctctacaaa tgtggtaaaa tcgataagga tctaggaacc 2940cctagtgatg gagttggcca ctccctctct gcgcgctcgc tcgctcactg aggccgcccg 3000ggcaaagccc gggcgtcggg cgacctttgg tcgcccggcc tcagtgagcg agcgagcgcg 3060cagagaggga gtggccaacc cccccccccc cccccctgca gcctggcgta atagcgaaga 3120ggcccgcacc gatcgccctt cccaacagtt gcgtagcctg aatggcgaat ggcgcgacgc 3180gccctgtagc ggcgcattaa gcgcggcggg tgtggtggtt acgcgcagcg tgaccgctac 3240acttgccagc gccctagcgc ccgctccttt cgctttcttc ccttcctttc tcgccacgtt 3300cgccggcttt ccccgtcaag ctctaaatcg ggggctccct ttagggttcc gatttagtgc 3360tttacggcac ctcgacccca aaaaacttga ttagggtgat ggttcacgta gtgggccatc 3420gccctgatag acggtttttc gccctttgac gttggagtcc acgttcttta atagtggact 3480cttgttccaa actggaacaa cactcaaccc tatctcggtc tattcttttg atttataagg 3540gattttgccg atttcggcct attggttaaa aaatgagctg atttaacaaa aatttaacgc 3600gaattttaac aaaatattaa cgtttacaat ttcctgatgc ggtattttct ccttacgcat 3660ctgtgcggta tttcacaccg catatggtgc actctcagta caatctgctc tgatgccgca 3720tagttaagcc agccccgaca cccgccaaca cccgctgacg cgccctgacg ggcttgtctg 3780ctcccggcat ccgcttacag acaagctgtg accgtctccg ggagctgcat gtgtcagagg 3840ttttcaccgt catcaccgaa acgcgcgaga cgaaagggcc tcgtgatacg cctattttta 3900taggttaatg tcatgataat aatggtttct tagacgtcag gtggcacttt tcggggaaat 3960gtgcgcggaa cccctatttg tttatttttc taaatacatt caaatatgta tccgctcatg 4020agacaataac cctgataaat gcttcaataa tattgaaaaa ggaagagtat gagtattcaa 4080catttccgtg tcgcccttat tccctttttt gcggcatttt gccttcctgt ttttgctcac 4140ccagaaacgc tggtgaaagt aaaagatgct gaagatcagt tgggtgcacg agtgggttac 4200atcgaactgg atctcaacag cggtaagatc cttgagagtt ttcgccccga agaacgtttt 4260ccaatgatga gcacttttaa agttctgcta tgtggcgcgg tattatcccg tattgacgcc 4320gggcaagagc aactcggtcg ccgcatacac tattctcaga atgacttggt tgagtactca 4380ccagtcacag aaaagcatct tacggatggc atgacagtaa gagaattatg cagtgctgcc 4440ataaccatga gtgataacac tgcggccaac ttacttctga caacgatcgg aggaccgaag 4500gagctaaccg cttttttgca caacatgggg gatcatgtaa ctcgccttga tcgttgggaa 4560ccggagctga atgaagccat accaaacgac gagcgtgaca ccacgatgcc tgtagcaatg 4620gcaacaacgt tgcgcaaact attaactggc gaactactta ctctagcttc ccggcaacaa 4680ttaatagact ggatggaggc ggataaagtt gcaggaccac ttctgcgctc ggcccttccg 4740gctggctggt ttattgctga taaatctgga gccggtgagc gtgggtctcg cggtatcatt 4800gcagcactgg ggccagatgg taagccctcc cgtatcgtag ttatctacac gacggggagt 4860caggcaacta tggatgaacg aaatagacag atcgctgaga taggtgcctc actgattaag 4920cattggtaac tgtcagacca agtttactca tatatacttt agattgattt aaaacttcat 4980ttttaattta aaaggatcta ggtgaagatc ctttttgata atctcatgac caaaatccct 5040taacgtgagt tttcgttcca ctgagcgtca gaccccgtag aaaagatcaa aggatcttct 5100tgagatcctt tttttctgcg cgtaatctgc tgcttgcaaa caaaaaaacc accgctacca 5160gcggtggttt gtttgccgga tcaagagcta ccaactcttt ttccgaaggt aactggcttc 5220agcagagcgc agataccaaa tactgtcctt ctagtgtagc cgtagttagg ccaccacttc 5280aagaactctg tagcaccgcc tacatacctc gctctgctaa tcctgttacc agtggctgct 5340gccagtggcg ataagtcgtg tcttaccggg ttggactcaa gacgatagtt accggataag 5400gcgcagcggt cgggctgaac ggggggttcg tgcacacagc ccagcttgga gcgaacgacc 5460tacaccgaac tgagatacct acagcgtgag cattgagaaa gcgccacgct tcccgaaggg 5520agaaaggcgg acaggtatcc ggtaagcggc agggtcggaa caggagagcg cacgagggag 5580cttccagggg gaaacgcctg gtatctttat agtcctgtcg ggtttcgcca cctctgactt 5640gagcgtcgat ttttgtgatg ctcgtcaggg gggcggagcc tatggaaaaa cgccagcaac 5700gcggcctttt tacggttcct ggccttttgc tggccttttg ctcacatgtt ctttcctgcg 5760ttatcccctg attctgtgga taaccgtatt accgcctttg agtgagctga taccgctcgc 5820cgcagccgaa cgaccgagcg cagcgagtca gtgagcgagg aagcggaaga gcgcccaata 5880cgcaaaccgc ctctccccgc gcgttggccg attcattaat gcagggctgc ag 5932 5 7492 DNA Artificial Sequence Description of Artificial Sequencep43C-AT-IN 5aattccgcat tgcagagata attgtattta agtgcctagc tcgatacaat aaacgccatt 60tgaccattca ccacattggt gtgcacctcc actagctgcc ttgactgcct ggccccccca 120tctctgtctt gcaggacaat gccgtcttct gtctcgtggg gcatcctcct gctggcaggc 180ctgtgctgcc tggtccctgt ctccctggct gaggatcccc agggagatgc tgcccagaag 240acagatacat cccaccatga tcaggatcac ccaaccttca acaagatcac ccccaacctg 300gctgagttcg ccttcagcct ataccgccag ctggcacacc agtccaacag caccaatatc 360ttcttctccc cagtgagcat cgctacagcc tttgcaatgc tctccctggg gaccaaggct 420gacactcacg atgaaatcct ggagggcctg aatttcaacc tcacggagat tccggaggct 480cagatccatg aaggcttcca ggaactcctc cgtaccctca accagccaga cagccagctc 540cagctgacca ccggcaatgg cctgttcctc agcgagggcc tgaagctagt ggataagttt 600ttggaggatg ttaaaaagtt gtaccactca gaagccttca ctgtcaactt cggggacacc 660gaagaggcca agaaacagat caacgattac gtggagaagg gtactcaagg gaaaattgtg 720gatttggtca aggagcttga cagagacaca gtttttgctc tggtgaatta catcttcttt 780aaaggtaagg ttgctcaacc agcctgagct gtttcccata gaaacaagca aaaatatttc 840tcaaaccatc agttcttgaa ctctccttgg caatgcatta tgggccatag caatgctttt 900cagcgtggat tcttcagttt tctacacaca aacactaaaa tgttttccat cattgagtaa 960tttgaggaaa taatagatta aactgtcaaa actactgacg ctctgcagaa cttttcagag 1020cctttaatgt ccttgtgtat actgtatatg tagaatatat aatgcttaga actatagaac 1080aaattgtaat acactgcata aagggatagt ttcatggaac atactttaca cgactctagt 1140gtcccagaat cagtatcagt tttgcaatct gaaagacctg ggttcaaatc ctgcctctaa 1200cacaattagc ttttgacaaa aacaatgcat tctacctctt tgaggtgcta atttctcatc 1260ttagcatgga caaaatacca ttcttgctgt caggtttttt taggattaaa caaatgacaa 1320agactgtggg gatggtgtgt ggcatacagc aggtgatgga ctcttctgta tctcaggctg 1380ccttcctgcc cctgaggggt taaaatgcca gggtcctggg ggccccaggg cattctaagc 1440cagctcccac tgtcccagga aaacagcata ggggagggga ggtgggaggc aaggccaggg 1500gctgcttcct ccactctgag gctcccttgc tcttgaggca aaggagggca gtggaggcaa 1560gccaggctgc agtcagcaca gctaaagtcc tggctctgct gtggccttag tgggggccca 1620ggtccctctc cagccccagt ctcctccttc tgtccaatga gaaagctggg atcaggggtc 1680cctgaggccc ctgtccactc tgcatgcctc gatggtgaag ctctgttggt atggcagagg 1740ggaggctgct caggcatctg catttcccct gccaatctag aggatgagga aagctctcag 1800gaatagtaag cagaatgttt gccctggatg aataactgag ctgccaatta acaaggggca 1860gggagcctta gacagaaggt accaaatatg cctgatgctc caacatttta tttgtaatat 1920ccaagacacc ctcaaataaa catatgattc caataaaaat gcacagccac gatggcatct 1980cttagcctga catcgccacg atgtagaaat tctgcatctt cctctagttt tgaattatcc 2040ccacacaatc tttttcggca gcttggatgg tcagtttcag caccttttac agatgatgaa 2100gctgagcctc gagggatgtg tgtcgtcaag ggggctcagg gcttctcagg gaggggactc 2160atggtttctt attctgctac actcttccaa accttcactc acccctggtg atgcccacct 2220tcccctctct ccaggcaaat gggagagacc ctttgaagtc aaggacaccg aggaagagga 2280cttccacgtg gaccaggtga ccaccgtgaa ggtgcctatg atgaagcgtt taggcatgtt 2340taacatccag cactgtaaga agctgtccag ctgggtgctg ctgatgaaat acctgggcaa 2400tgccaccgcc atcttcttcc tgcctgatga ggggaaacta cagcacctgg aaaatgaact 2460cacccacgat atcatcacca agttcctgga aaatgaagac agaaggtctg ccagcttaca 2520tttacccaaa ctgtccatta ctggaaccta tgatctgaag agcgtcctgg gtcaactggg 2580catcactaag gtcttcagca atggggctga cctctccggg gtcacagagg aggcacccct 2640gaagctctcc aaggccgtgc ataaggctgt gctgaccatc gacgagaaag ggactgaagc 2700tgctggggcc atgtttttag aggccatacc catgtctatc ccccccgagg tcaagttcaa 2760caaacccttt gtcttcttaa tgattgaaca aaataccaag tctcccctct tcatgggaaa 2820agtggtgaat cccacccaaa aataactgcc tctcgctcct caacccctcc cctccatccc 2880tggccccctc cctggatgac attaaagaag ggttgagctg gtaacccccc ccccccctgc 2940aggccctcga gacgcgtggc atgcaagctt ggtaccgagc tcggatccac tagtaacggc 3000cgccagtgtg ctggaattca cgcgtggtac ctctagagtc gacccgggcg gccgcttcga 3060gcagacatga taagatacat tgatgagttt ggacaaacca caactagaat gcagtgaaaa 3120aaatgcttta tttgtgaaat ttgtgatgct attgctttat ttgtaaccat tataagctgc 3180aataaacaag ttaacaacaa caattgcatt cattttatgt ttcaggttca gggggagatg 3240tgggaggttt tttaaagcaa gtaaaacctc tacaaatgtg gtaaaatcga taaggatcta 3300ggaaccccta gtgatggagt tggccactcc ctctctgcgc gctcgctcgc tcactgaggc 3360cgcccgggca aagcccgggc gtcgggcgac ctttggtcgc ccggcctcag tgagcgagcg 3420agcgcgcaga gagggagtgg ccaactgcag ctgcattaat gaatcggcca acgcgcgggg 3480agaggcggtt tgcgtattgg gcgctcttcc gcttcctcgc tcactgactc gctgcgctcg 3540gtcgttcggc tgcggcgagc ggtatcagct cactcaaagg cggtaatacg gttatccaca 3600gaatcagggg ataacgcagg aaagaacatg tgagcaaaag gccagcaaaa ggccaggaac 3660cgtaaaaagg ccgcgttgct ggcgtttttc cataggctcc gcccccctga cgagcatcac 3720aaaaatcgac gctcaagtca gaggtggcga aacccgacag gactataaag ataccaggcg 3780tttccccctg gaagctccct cgtgcgctct cctgttccga ccctgccgct taccggatac 3840ctgtccgcct ttctcccttc gggaagcgtg gcgctttctc aatgctcacg ctgtaggtat 3900ctcagttcgg tgtaggtcgt tcgctccaag ctgggctgtg tgcacgaacc ccccgttcag 3960cccgaccgct gcgccttatc cggtaactat cgtcttgagt ccaacccggt aagacacgac 4020ttatcgccac tggcagcagc cactggtaac aggattagca gagcgaggta tgtaggcggt 4080gctacagagt tcttgaagtg gtggcctaac tacggctaca ctagaaggac agtatttggt 4140atctgcgctc tgctgaagcc agttaccttc ggaaaaagag ttggtagctc ttgatccggc 4200aaacaaacca ccgctggtag cggtggtttt tttgtttgca agcagcagat tacgcgcaga 4260aaaaaaggat ctcaagaaga tcctttgatc ttttctacgg ggtctgacgc tcagtggaac 4320gaaaactcac gttaagggat tttggtcatg agattatcaa aaaggatctt cacctagatc 4380cttttaaatt aaaaatgaag ttttaaatca atctaaagta tatatgagta aacttggtct 4440gacagttacc aatgcttaat cagtgaggca cctatctcag cgatctgtct atttcgttca 4500tccatagttg cctgactccc cgtcgtgtag ataactacga tacgggaggg cttaccatct 4560ggccccagtg ctgcaatgat accgcgagac ccacgctcac cggctccaga tttatcagca 4620ataaaccagc cagccggaag ggccgagcgc agaagtggtc ctgcaacttt atccgcctcc 4680atccagtcta ttaattgttg ccgggaagct agagtaagta gttcgccagt taatagtttg 4740cgcaacgttg ttgccattgc tacaggcatc gtggtgtcac gctcgtcgtt tggtatggct 4800tcattcagct ccggttccca acgatcaagg cgagttacat gatcccccat gttgtgcaaa 4860aaagcggtta gctccttcgg tcctccgatc gttgtcagaa gtaagttggc cgcagtgtta 4920tcactcatgg ttatggcagc actgcataat tctcttactg tcatgccatc cgtaagatgc 4980ttttctgtga ctggtgagta ctcaaccaag tcattctgag aatagtgtat gcggcgaccg 5040agttgctctt gcccggcgtc aatacgggat aataccgcgc cacatagcag aactttaaaa 5100gtgctcatca ttggaaaacg ttcttcgggg cgaaaactct caaggatctt accgctgttg 5160agatccagtt cgatgtaacc cactcgtgca cccaactgat cttcagcatc ttttactttc 5220accagcgttt ctgggtgagc aaaaacagga aggcaaaatg ccgcaaaaaa gggaataagg 5280gcgacacgga aatgttgaat actcatactc ttcctttttc aatattattg aagcatttat 5340cagggttatt gtctcatgag cggatacata tttgaatgta tttagaaaaa taaacaaata 5400ggggttccgc gcacatttcc ccgaaaagtg ccacctgacg tctaagaaac cattattatc 5460atgacattaa cctataaaaa taggcgtatc acgaggccct ttcgtctcgc gcgtttcggt 5520gatgacggtg aaaacctctg acacatgcag ctcccggaga cggtcacagc ttgtctgtaa 5580gcggatgccg ggagcagaca agcccgtcag ggcgcgtcag cgggtgttgg cgggtgtcgg 5640ggctggctta actatgcggc atcagagcag attgtactga gagtgcacca tatgcggtgt 5700gaaataccgc acagatgcgt aaggagaaaa taccgcatca ggaaattgta aacgttaata 5760ttttgttaaa attcgcgtta aatttttgtt aaatcagctc attttttaac caataggccg 5820aaatcggcaa aatcccttat aaatcaaaag aatagaccga gatagggttg agtgttgttc 5880cagtttggaa caagagtcca ctattaaaga acgtggactc caacgtcaaa gggcgaaaaa 5940ccgtctatca gggcgatggc ccactacgtg aaccatcacc ctaatcaagt tttttggggt 6000cgaggtgccg taaagcacta aatcggaacc ctaaagggag cccccgattt agagcttgac 6060ggggaaagcc ggcgaacgtg gcgagaaagg aagggaagaa agcgaaagga gcgggcgcta 6120gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac cacacccgcc gcgcttaatg 6180cgccgctaca gggcgcgtcg cgccattcgc cattcaggct acgcaactgt tgggaagggc 6240gatcggtgcg ggcctcttcg ctattacgcc agctgcagtt ggccactccc tctctgcgcg 6300ctcgctcgct cactgaggcc gggcgaccaa aggtcgcccg acgcccgggc tttgcccggg 6360cggcctcagt gagcgagcga gcgcgcagag agggagtggc caactccatc actaggggtt 6420cctagatctt caatattggc cattagccat attattcatt ggttatatag cataaatcaa 6480tattggctat tggccattgc atacgttgta tctatatcat aatatgtaca tttatattgg 6540ctcatgtcca atatgaccgc catgttggca ttgattattg actagttatt aatagtaatc 6600aattacgggg tcattagttc atagcccata tatggagttc cgcgttacat aacttacggt 6660aaatggcccg cctggctgac cgcccaacga cccccgccca ttgacgtcaa taatgacgta 6720tgttcccata gtaacgccaa tagggacttt ccattgacgt caatgggtgg agtatttacg 6780gtaaactgcc cacttggcag tacatcaagt gtatcatatg ccaagtccgc cccctattga 6840cgtcaatgac ggtaaatggc ccgcctggca ttatgcccag tacatgacct tacgggactt 6900tcctacttgg cagtacatct acgtattagt catcgctatt accatggtga tgcggttttg 6960gcagtacacc aatgggcgtg gatagcggtt tgactcacgg ggatttccaa gtctccaccc 7020cattgacgtc aatgggagtt tgttttggca ccaaaatcaa cgggactttc caaaatgtcg 7080taataacccc gccccgttga cgcaaatggg cggtaggcgt gtacggtggg aggtctatat 7140aagcagagct cgtttagtga accgtcagat cactagaagc tttattgcgg tagtttatca 7200cagttaaatt gctaacgcag tcagtgcttc tgacacaaca gtctcgaact taagctgcag 7260aagttggtcg tgaggcactg ggcaggtaag tatcaaggtt acaagacagg tttaaggaga 7320ccaatagaaa ctgggcttgt cgagacagag aagactcttg cgtttctgat aggcacctat 7380tggtcttact gacatccact ttgcctttct ctccacaggt gtccactccc agttcaatta 7440cagctcttaa ggctagagta cttaatacga ctcactatag gctagcctcg ag 7492 6 6714 DNA Artificial Sequence Description of Artificial SequencePLASMID p43CB-AT 6gggggggggg gggggggttg gccactccct ctctgcgcgc tcgctcgctc actgaggccg 60ggcgaccaaa ggtcgcccga cgcccgggct ttgcccgggc ggcctcagtg agcgagcgag 120cgcgcagaga gggagtggcc aactccatca ctaggggttc ctagatcttc aatattggcc 180attagccata ttattcattg gttatatagc ataaatcaat attggctatt ggccattgca 240tacgttgtat ctatatcata atatgtacat ttatattggc tcatgtccaa tatgaccgcc 300atgttggcat tgattattga ctagttatta atagtaatca attacggggt cattagttca 360tagcccatat atggagttcc gcgttacata acttacggta aatggcccgc ctggctgacc 420gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat 480agggactttc cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt 540acatcaagtg tatcatatgc caagtccgcc ccctattgac gtcaatgacg gtaaatggcc 600cgcctggcat tatgcccagt acatgacctt acgggacttt cctacttggc agtacatcta 660cgtattagtc atcgctatta ccatggtcga ggtgagcccc acgttctgct tcactctccc 720catctccccc ccctccccac ccccaatttt gtatttattt attttttaat tattttgtgc 780agcgatgggg gcgggggggg ggggggggcg cgcgccaggc ggggcggggc ggggcgaggg 840gcggggcggg gcgaggcgga gaggtgcggc ggcagccaat cagagcggcg cgctccgaaa 900gtttcctttt atggcgaggc ggcggcggcg gcggccctat aaaaagcgaa gcgcgcggcg 960ggcgggagtc gctgcgacgc tgccttcgcc ccgtgccccg ctccgccgcc gcctcgcgcc 1020gcccgccccg gctctgactg accgcgttac tcccacaggt gagcgggcgg gacggccctt 1080ctcctccggg ctgtaattag cgcttggttt aatgacggct tgtttctttt ctgtggctgc 1140gtgaaagcct tgaggggctc cgggagggcc ctttgtgcgg gggggagcgg ctcggggggt 1200gcgtgcgtgt gtgtgtgcgt ggggagcgcc gcgtgcggcc cgcgctgccc ggcggctgtg 1260agcgctgcgg gcgcggcgcg gggctttgtg cgctccgcag tgtgcgcgag gggagcgcgg 1320ccgggggcgg tgccccgcgg tgcggggggg gctgcgaggg gaacaaaggc tgcgtgcggg 1380gtgtgtgcgt gggggggtga gcagggggtg tgggcgcggc ggtcgggctg taaccccccc 1440ctgcaccccc ctccccgagt tgctgagcac ggcccggctt cgggtgcggg gctccgtacg 1500gggcgtggcg cggggctcgc cgtgccgggc ggggggtggc ggcaggtggg ggtgccgggc 1560ggggcggggc cgcctcgggc cggggagggc tcgggggagg ggcgcggcgg cccccggagc 1620gccggcggct gtcgaggcgc ggcgagccgc agccattgcc ttttatggta atcgtgcgag 1680agggcgcagg gacttccttt gtcccaaatc tgtgcggagc cgaaatctgg gaggcgccgc 1740cgcaccccct ctagcgggcg cggggcgaag cggtgcggcg ccggcaggaa ggaaatgggc 1800ggggagggcc ttcgtgcgtc gccgcgccgc cgtccccttc tccctctcca gcctcggggc 1860tgtccgcggg gggacggctg ccttcggggg ggacggggca gggcggggtt cggcttctgg 1920cgtgtgaccg gcggctctag agcctctgct aaccatgttc atgccttctt ctttttccta 1980cagctcctgg gcaacgtgct ggttattgtg ctgtctcatc attttggcaa agaattcgat 2040atcaagcttg gggattttca ggcaccacca ctgacctggg acagtgaatc gacaatgccg 2100tcttctgtct cgtggggcat cctcctgctg gcaggcctgt gctgcctggt ccctgtctcc 2160ctggctgagg atccccaggg agatgctgcc cagaagacag atacatccca ccatgatcag 2220gatcacccaa ccttcaacaa gatcaccccc aacctggctg agttcgcctt cagcctatac 2280cgccagctgg cacaccagtc caacagcacc aatatcttct tctccccagt gagcatcgct 2340acagcctttg caatgctctc cctggggacc aaggctgaca ctcacgatga aatcctggag 2400ggcctgaatt tcaacctcac ggagattccg gaggctcaga tccatgaagg cttccaggaa 2460ctcctccgta ccctcaacca gccagacagc cagctccagc tgaccaccgg caatggcctg 2520ttcctcagcg agggcctgaa gctagtggat aagtttttgg aggatgttaa aaagttgtac 2580cactcagaag ccttcactgt caacttcggg gacaccgaag aggccaagaa acagatcaac 2640gattacgtgg agaagggtac tcaagggaaa attgtggatt tggtcaagga gcttgacaga 2700gacacagttt ttgctctggt gaattacatc ttctttaaag gcaaatggga gagacccttt 2760gaagtcaagg acaccgagga agaggacttc cacgtggacc aggtgaccac cgtgaaggtg 2820cctatgatga agcgtttagg catgtttaac atccagcact gtaagaagct gtccagctgg 2880gtgctgctga tgaaatacct gggcaatgcc accgccatct tcttcctgcc tgatgagggg 2940aaactacagc acctggaaaa tgaactcacc cacgatatca tcaccaagtt cctggaaaat 3000gaagacagaa ggtctgccag cttacattta cccaaactgt ccattactgg aacctatgat 3060ctgaagagcg tcctgggtca actgggcatc actaaggtct tcagcaatgg ggctgacctc 3120tccggggtca cagaggaggc acccctgaag ctctccaagg ccgtgcataa ggctgtgctg 3180accatcgacg agaaagggac tgaagctgct ggggccatgt ttttagaggc catacccatg 3240tctatccccc ccgaggtcaa gttcaacaaa ccctttgtct tcttaatgat tgaacaaaat 3300accaagtctc ccctcttcat gggaaaagtg gtgaatccca cccaaaaata actgcctctc 3360gctcctcaac ccctcccctc catccctggc cccctccctg gatgacatta aagaagggtt 3420gagctggtaa cccccccccc ccctgcaggg gccctcgacc cgggcggccg cttcgagcag 3480acatgataag atacattgat gagtttggac aaaccacaac tagaatgcag tgaaaaaaat 3540gctttatttg tgaaatttgt gatgctattg ctttatttgt aaccattata agctgcaata 3600aacaagttaa caacaacaat tgcattcatt ttatgtttca ggttcagggg gagatgtggg 3660aggtttttta aagcaagtaa aacctctaca aatgtggtaa aatcgataag gatctaggaa 3720cccctagtga tggagttggc cactccctct ctgcgcgctc gctcgctcac tgaggccgcc 3780cgggcaaagc ccgggcgtcg ggcgaccttt ggtcgcccgg cctcagtgag cgagcgagcg 3840cgcagagagg gagtggccaa cccccccccc cccccccctg cagcctggcg taatagcgaa 3900gaggcccgca ccgatcgccc ttcccaacag ttgcgtagcc tgaatggcga atggcgcgac 3960gcgccctgta gcggcgcatt aagcgcggcg ggtgtggtgg ttacgcgcag cgtgaccgct 4020acacttgcca gcgccctagc gcccgctcct ttcgctttct tcccttcctt tctcgccacg 4080ttcgccggct ttccccgtca agctctaaat cgggggctcc ctttagggtt ccgatttagt 4140gctttacggc acctcgaccc caaaaaactt gattagggtg atggttcacg tagtgggcca 4200tcgccctgat agacggtttt tcgccctttg acgttggagt ccacgttctt taatagtgga 4260ctcttgttcc aaactggaac aacactcaac cctatctcgg tctattcttt tgatttataa 4320gggattttgc cgatttcggc ctattggtta aaaaatgagc tgatttaaca aaaatttaac 4380gcgaatttta acaaaatatt aacgtttaca atttcctgat gcggtatttt ctccttacgc 4440atctgtgcgg tatttcacac cgcatatggt gcactctcag tacaatctgc tctgatgccg 4500catagttaag ccagccccga cacccgccaa cacccgctga cgcgccctga cgggcttgtc 4560tgctcccggc atccgcttac agacaagctg tgaccgtctc cgggagctgc atgtgtcaga 4620ggttttcacc gtcatcaccg aaacgcgcga gacgaaaggg cctcgtgata cgcctatttt 4680tataggttaa tgtcatgata ataatggttt cttagacgtc aggtggcact tttcggggaa 4740atgtgcgcgg aacccctatt tgtttatttt tctaaataca ttcaaatatg tatccgctca 4800tgagacaata accctgataa atgcttcaat aatattgaaa aaggaagagt atgagtattc 4860aacatttccg tgtcgccctt attccctttt ttgcggcatt ttgccttcct gtttttgctc 4920acccagaaac gctggtgaaa gtaaaagatg ctgaagatca gttgggtgca cgagtgggtt 4980acatcgaact ggatctcaac agcggtaaga tccttgagag ttttcgcccc gaagaacgtt 5040ttccaatgat gagcactttt aaagttctgc tatgtggcgc ggtattatcc cgtattgacg 5100ccgggcaaga gcaactcggt cgccgcatac actattctca gaatgacttg gttgagtact 5160caccagtcac agaaaagcat cttacggatg gcatgacagt aagagaatta tgcagtgctg 5220ccataaccat gagtgataac actgcggcca acttacttct gacaacgatc ggaggaccga 5280aggagctaac cgcttttttg cacaacatgg gggatcatgt aactcgcctt gatcgttggg 5340aaccggagct gaatgaagcc ataccaaacg acgagcgtga caccacgatg cctgtagcaa 5400tggcaacaac gttgcgcaaa ctattaactg gcgaactact tactctagct tcccggcaac 5460aattaataga ctggatggag gcggataaag ttgcaggacc acttctgcgc tcggcccttc 5520cggctggctg gtttattgct gataaatctg gagccggtga gcgtgggtct cgcggtatca 5580ttgcagcact ggggccagat ggtaagccct cccgtatcgt agttatctac acgacgggga 5640gtcaggcaac tatggatgaa cgaaatagac agatcgctga gataggtgcc tcactgatta 5700agcattggta actgtcagac caagtttact catatatact ttagattgat ttaaaacttc 5760atttttaatt taaaaggatc taggtgaaga tcctttttga taatctcatg accaaaatcc 5820cttaacgtga gttttcgttc cactgagcgt cagaccccgt agaaaagatc aaaggatctt 5880cttgagatcc tttttttctg cgcgtaatct gctgcttgca aacaaaaaaa ccaccgctac 5940cagcggtggt ttgtttgccg gatcaagagc taccaactct ttttccgaag gtaactggct 6000tcagcagagc gcagatacca aatactgtcc ttctagtgta gccgtagtta ggccaccact 6060tcaagaactc tgtagcaccg cctacatacc tcgctctgct aatcctgtta ccagtggctg 6120ctgccagtgg cgataagtcg tgtcttaccg ggttggactc aagacgatag ttaccggata 6180aggcgcagcg gtcgggctga acggggggtt cgtgcacaca gcccagcttg gagcgaacga 6240cctacaccga actgagatac ctacagcgtg agcattgaga aagcgccacg cttcccgaag 6300ggagaaaggc ggacaggtat ccggtaagcg gcagggtcgg aacaggagag cgcacgaggg 6360agcttccagg gggaaacgcc tggtatcttt atagtcctgt cgggtttcgc cacctctgac 6420ttgagcgtcg atttttgtga tgctcgtcag gggggcggag cctatggaaa aacgccagca 6480acgcggcctt tttacggttc ctggcctttt gctggccttt tgctcacatg ttctttcctg 6540cgttatcccc tgattctgtg gataaccgta ttaccgcctt tgagtgagct gataccgctc 6600gccgcagccg aacgaccgag cgcagcgagt cagtgagcga ggaagcggaa gagcgcccaa 6660tacgcaaacc gcctctcccc gcgcgttggc cgattcatta atgcagggct gcag 6714 7 6981 DNA Artificial Sequence Description of Artificial SequencePLASMID C-AT2 7ctagaactag tggatccccc gggctgcagg aattcgatat caagcttggg gattttcagg 60caccaccact gacctgggac agtgaatcga caatgccgtc ttctgtctcg tggggcatcc 120tcctgctggc aggcctgtgc tgcctggtcc ctgtctccct ggctgaggat ccccagggag 180atgctgccca gaagacagat acatcccacc atgatcagga tcacccaacc ttcaacaaga 240tcacccccaa cctggctgag ttcgccttca gcctataccg ccagctggca caccagtcca 300acagcaccaa tatcttcttc tccccagtga gcatcgctac agcctttgca atgctctccc 360tggggaccaa ggctgacact cacgatgaaa tcctggaggg cctgaatttc aacctcacgg 420agattccgga ggctcagatc catgaaggct tccaggaact cctccgtacc ctcaaccagc 480cagacagcca gctccagctg accaccggca atggcctgtt cctcagcgag ggcctgaagc 540tagtggataa gtttttggag gatgttaaaa agttgtacca ctcagaagcc ttcactgtca 600acttcgggga caccgaagag gccaagaaac agatcaacga ttacgtggag aagggtactc 660aagggaaaat tgtggatttg gtcaaggagc ttgacagaga cacagttttt gctctggtga 720attacatctt ctttaaaggc aaatgggaga gaccctttga agtcaaggac accgaggaag 780aggacttcca cgtggaccag gtgaccaccg tgaaggtgcc tatgatgaag cgtttaggca 840tgtttaacat ccagcactgt aagaagctgt ccagctgggt gctgctgatg aaatacctgg 900gcaatgccac cgccatcttc ttcctgcctg atgaggggaa actacagcac ctggaaaatg 960aactcaccca cgatatcatc accaagttcc tggaaaatga agacagaagg tctgccagct 1020tacatttacc caaactgtcc attactggaa cctatgatct gaagagcgtc ctgggtcaac 1080tgggcatcac taaggtcttc agcaatgggg ctgacctctc cggggtcaca gaggaggcac 1140ccctgaagct ctccaaggcc gtgcataagg ctgtgctgac catcgacgag aaagggactg 1200aagctgctgg ggccatgttt ttagaggcca tacccatgtc tatccccccc gaggtcaagt 1260tcaacaaacc ctttgtcttc ttaatgattg aacaaaatac caagtctccc ctcttcatgg 1320gaaaagtggt gaatcccacc caaaaataac tgcctctcgc tcctcaaccc ctcccctcca 1380tccctggccc cctccctgga tgacattaaa gaagggttga gctggtaacc cccccccccc 1440ctgcaggggc cctcgaggcc gcggggatcc agacatgata agatacattg atgagtttgg 1500acaaaccaca actagaatgc agtgaaaaaa atgctttatt tgtgaaattt gtgatgctat 1560tgctttattt gtaaccatta taagctgcaa taaacaagtt aacaacaaca attgcattca 1620ttttatgttt caggttcagg gggaggtgtg ggaggttttt tagtcgacct cgagcagtgt 1680ggttttgcaa gaggaagcaa aaagcctctc cacccaggcc tggaatgttt ccacccaagt 1740cgaaggcagt gtggttttgc aagaggaagc aaaaagcctc tccacccagg cctggaatgt 1800ttccacccaa tgtcgagcaa ccccgcccag cgtcttgtca ttggcgaatt cgaacacgca 1860gatgcagtcg gggcggcgcg gtcccaggtc cacttcgcat attaaggtga cgcgtgtggc 1920ctcgaacacc gagcgaccct gcagccaata tgggatcggc cattgaacaa gatggattgc 1980acgcaggttc tccggccgct tgggtggaga ggctattcgg ctatgactgg gcacaacaga 2040caatcggctg ctctgatgcc gccgtgttcc ggctgtcagc gcaggggcgc ccggttcttt 2100ttgtcaagac cgacctgtcc ggtgccctga atgaactgca ggacgaggca gcgcggctat 2160cgtggctggc cacgacgggc gttccttgcg cagctgtgct cgacgttgtc actgaagcgg 2220gaagggactg gctgctattg ggcgaagtgc cggggcagga tctcctgtca tctcaccttg 2280ctcctgccga gaaagtatcc atcatggctg atgcaatgcg gcggctgcat acgcttgatc 2340cggctacctg cccattcgac caccaagcga aacatcgcat cgagcgagca cgtactcgga 2400tggaagccgg tcttgtcgat caggatgatc tggacgaaga gcatcagggg ctcgcgccag 2460ccgaactgtt cgccaggctc aaggcgcgca tgcccgacgg cgaggatctc gtcgtgaccc 2520atggcgatgc ctgcttgccg aatatcatgg tggaaaatgg ccgcttttct ggattcatcg 2580actgtggccg gctgggtgtg gcggaccgct atcaggacat agcgttggct acccgtgata 2640ttgctgaaga gcttggcggc gaatgggctg accgcttcct cgtgctttac ggtatcgccg 2700ctcccgattc gcagcgcatc gccttctatc gccttcttga cgagttcttc tgaggggatc 2760cgtcgactag agctcgctga tcagcctcga ctgtgccttc tagttgccag ccatctgttg 2820tttgcccctc ccccgtgcct tccttgaccc tggaaggtgc cactcccact gtcctttcct 2880aataaaatga ggaaattgca tcgcattgtc tgagtaggtg tcattctatt ctggggggtg 2940gggtggggca ggacagcaag ggggaggatt gggaagacaa tagcaggcat gctggggaga 3000gatctaggaa cccctagtga tggagttggc cactccctct ctgcgcgctc gctcgctcac 3060tgaggccgcc cgggcaaagc ccgggcgtcg ggcgaccttt ggtcgcccgg cctcagtgag 3120cgagcgagcg cgcagagagg gagtggccaa cccccccccc cccccccctg cagccctgca 3180ttaatgaatc ggccaacgcg cggggagagg cggtttgcgt attgggcgct cttccgcttc 3240ctcgctcact gactcgctgc gctcggtcgt tcggctgcgg cgagcggtat cagctcactc 3300aaaggcggta atacggttat ccacagaatc aggggataac gcaggaaaga acatgtgagc 3360aaaaggccag caaaaggcca ggaaccgtaa aaaggccgcg ttgctggcgt ttttccatag 3420gctccgcccc cctgacgagc atcacaaaaa tcgacgctca agtcagaggt ggcgaaaccc 3480gacaggacta taaagatacc aggcgtttcc ccctggaagc tccctcgtgc gctctcctgt 3540tccgaccctg ccgcttaccg gatacctgtc cgcctttctc ccttcgggaa gcgtggcgct 3600ttctcaatgc tcacgctgta ggtatctcag ttcggtgtag gtcgttcgct ccaagctggg 3660ctgtgtgcac gaaccccccg ttcagcccga ccgctgcgcc ttatccggta actatcgtct 3720tgagtccaac ccggtaagac acgacttatc gccactggca gcagccactg gtaacaggat 3780tagcagagcg aggtatgtag gcggtgctac agagttcttg aagtggtggc ctaactacgg 3840ctacactaga aggacagtat ttggtatctg cgctctgctg aagccagtta ccttcggaaa 3900aagagttggt agctcttgat ccggcaaaca aaccaccgct ggtagcggtg gtttttttgt 3960ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt tgatcttttc 4020tacggggtct gacgctcagt ggaacgaaaa ctcacgttaa gggattttgg tcatgagatt 4080atcaaaaagg atcttcacct agatcctttt aaattaaaaa tgaagtttta aatcaatcta 4140aagtatatat gagtaaactt ggtctgacag ttaccaatgc ttaatcagtg aggcacctat 4200ctcagcgatc tgtctatttc gttcatccat agttgcctga ctccccgtcg tgtagataac 4260tacgatacgg gagggcttac catctggccc cagtgctgca atgataccgc gagacccacg 4320ctcaccggct ccagatttat cagcaataaa ccagccagcc ggaagggccg agcgcagaag 4380tggtcctgca actttatccg cctccatcca gtctattaat tgttgccggg aagctagagt 4440aagtagttcg ccagttaata gtttgcgcaa cgttgttgcc attgctacag gcatcgtggt 4500gtcacgctcg tcgtttggta tggcttcatt cagctccggt tcccaacgat caaggcgagt 4560tacatgatcc cccatgttgt gcaaaaaagc ggttagctcc ttcggtcctc cgatcgttgt 4620cagaagtaag ttggccgcag tgttatcact catggttatg gcagcactgc ataattctct 4680tactgtcatg ccatccgtaa gatgcttttc tgtgactggt gagtactcaa ccaagtcatt 4740ctgagaatag tgtatgcggc gaccgagttg ctcttgcccg gcgtcaatac gggataatac 4800cgcgccacat agcagaactt taaaagtgct catcattgga aaacgttctt cggggcgaaa 4860actctcaagg atcttaccgc tgttgagatc cagttcgatg taacccactc gtgcacccaa 4920ctgatcttca gcatctttta ctttcaccag cgtttctggg tgagcaaaaa caggaaggca 4980aaatgccgca aaaaagggaa taagggcgac acggaaatgt tgaatactca tactcttcct 5040ttttcaatat tattgaagca tttatcaggg ttattgtctc atgagcggat acatatttga 5100atgtatttag aaaaataaac aaataggggt tccgcgcaca tttccccgaa aagtgccacc 5160tgacgtctaa gaaaccatta ttatcatgac attaacctat aaaaataggc gtatcacgag 5220gccctttcgt ctcgcgcgtt tcggtgatga cggtgaaaac ctctgacaca tgcagctccc 5280ggagacggtc acagcttgtc tgtaagcgga tgccgggagc agacaagccc gtcagggcgc 5340gtcagcgggt gttggcgggt gtcggggctg gcttaactat gcggcatcag agcagattgt 5400actgagagtg caccatatgc ggtgtgaaat accgcacaga tgcgtaagga gaaaataccg 5460catcaggaaa ttgtaaacgt taatattttg ttaaaattcg cgttaaattt ttgttaaatc 5520agctcatttt ttaaccaata ggccgaaatc ggcaaaatcc cttataaatc aaaagaatag 5580accgagatag ggttgagtgt tgttccagtt tggaacaaga gtccactatt aaagaacgtg 5640gactccaacg tcaaagggcg aaaaaccgtc tatcagggcg atggcccact acgtgaacca 5700tcaccctaat caagtttttt ggggtcgagg tgccgtaaag cactaaatcg gaaccctaaa 5760gggagccccc gatttagagc ttgacgggga aagccggcga acgtggcgag aaaggaaggg 5820aagaaagcga aaggagcggg cgctagggcg ctggcaagtg tagcggtcac gctgcgcgta 5880accaccacac ccgccgcgct taatgcgccg ctacagggcg cgtcgcgcca ttcgccattc 5940aggctacgca actgttggga agggcgatcg gtgcgggcct cttcgctatt acgccaggct 6000gcaggggggg gggggggggg gttggccact ccctctctgc gcgctcgctc gctcactgag 6060gccgggcgac caaaggtcgc ccgacgcccg ggctttgccc gggcggcctc agtgagcgag 6120cgagcgcgca gagagggagt ggccaactcc atcactaggg gttcctagat ctgaattcgg 6180tacccgttac ataacttacg gtaaatggcc cgcctggctg accgcccaac gacccccgcc 6240cattgacgtc aataatgacg tatgttccca tagtaacgcc aatagggact ttccattgac 6300gtcaatgggt ggagtattta cggtaaactg cccacttggc agtacatcaa gtgtatcata 6360tgccaagtac gccccctatt gacgtcaatg acggtaaatg gcccgcctgg cattatgccc 6420agtacatgac cttatgggac tttcctactt ggcagtacat ctacgtatta gtcatcgcta 6480ttaccatggt gatgcggttt tggcagtaca tcaatgggcg tggatagcgg tttgactcac 6540ggggatttcc aagtctccac cccattgacg tcaatgggag tttgttttgg caccaaaatc 6600aacgggactt tccaaaatgt cgtaacaact ccgccccatt gacgcaaatg ggcggtaggc 6660gtgtacggtg ggaggtctat ataagcagag ctcgtttagt gaaccgtcag atcgcctgga 6720gacgccatcc acgctgtttt gacctccata gaagacaccg ggaccgatcc agcctccgga 6780ctctagagga tccggtactc gaggaactga aaaaccagaa agttaactgg taagtttagt 6840ctttttgtct tttatttcag gtcccggatc cggtggtggt gcaaatcaaa gaactgctcc 6900tcagtggatg ttgcctttac ttctaggcct gtacggaagt gttacttctg ctctaaaagc 6960tgcggaattg tacccgcggc c 6981 8 6142 DNA Artificial Sequence Description of Artificial SequencePLASMID p43msENC-AT 8gggggggggg gggggggttg gccactccct ctctgcgcgc tcgctcgctc actgaggccg 60ggcgaccaaa ggtcgcccga cgcccgggct ttgcccgggc ggcctcagtg agcgagcgag 120cgcgcagaga gggagtggcc aactccatca ctaggggttc ctagatctca ccattcctca 180cgacacccaa atatggcgac gggtgaggaa tggtggggag ttatttttag agcggtgagg 240aatggtgggc aggcagcagg tgttggcgct ctaaaaataa ctcccgggag ttatttttag 300agcggtgagg aatggtggac acccaaatat ggcgacggca ccattcctca ccccaggcca 360tatttgggtg tcagatcttc aatattggcc attagccata ttattcattg gttatatagc 420ataaatcaat attggctatt ggccattgca tacgttgtat ctatatcata atatgtacat 480ttatattggc tcatgtccaa tatgaccgcc atgttggcat tgattattga ctagttatta 540atagtaatca attacggggt cattagttca tagcccatat atggagttcc gcgttacata 600acttacggta aatggcccgc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat 660aatgacgtat gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga 720gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc caagtccgcc 780ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt 840acgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta ccatggtgat 900gcggttttgg cagtacacca atgggcgtgg atagcggttt gactcacggg gatttccaag 960tctccacccc attgacgtca atgggagttt gttttggcac caaaatcaac gggactttcc 1020aaaatgtcgt aataaccccg ccccgttgac gcaaatgggc ggtaggcgtg tacggtggga 1080ggtctatata agcagagctc gtttagtgaa ccgtcagatc actagaagct ttattgcggt 1140agtttatcac agttaaattg ctaacgcagt cagtgcttct gacacaacag tctcgaactt 1200aagctgcaga agttggtcgt gaggcactgg gcaggtaagt atcaaggtta caagacaggt 1260ttaaggagac caatagaaac tgggcttgtc gagacagaga agactcttgc gtttctgata 1320ggcacctatt ggtcttactg acatccactt tgcctttctc tccacaggtg tccactccca 1380gttcaattac agctcttaag gctagagtac ttaatacgac tcactatagg ctagaactag 1440tggatccccc gggctgcagg aattcgatat caagcttggg gattttcagg caccaccact 1500gacctgggac agtgaatcga caatgccgtc ttctgtctcg tggggcatcc tcctgctggc 1560aggcctgtgc tgcctggtcc ctgtctccct ggctgaggat ccccagggag atgctgccca 1620gaagacagat acatcccacc atgatcagga tcacccaacc ttcaacaaga tcacccccaa 1680cctggctgag ttcgccttca gcctataccg ccagctggca caccagtcca acagcaccaa 1740tatcttcttc tccccagtga gcatcgctac agcctttgca atgctctccc tggggaccaa 1800ggctgacact cacgatgaaa tcctggaggg cctgaatttc aacctcacgg agattccgga 1860ggctcagatc catgaaggct tccaggaact cctccgtacc ctcaaccagc cagacagcca 1920gctccagctg accaccggca atggcctgtt cctcagcgag ggcctgaagc tagtggataa 1980gtttttggag gatgttaaaa agttgtacca ctcagaagcc ttcactgtca acttcgggga 2040caccgaagag gccaagaaac agatcaacga ttacgtggag aagggtactc aagggaaaat 2100tgtggatttg gtcaaggagc ttgacagaga cacagttttt gctctggtga attacatctt 2160ctttaaaggc aaatgggaga gaccctttga agtcaaggac accgaggaag aggacttcca 2220cgtggaccag gtgaccaccg tgaaggtgcc tatgatgaag cgtttaggca tgtttaacat 2280ccagcactgt aagaagctgt ccagctgggt gctgctgatg aaatacctgg gcaatgccac 2340cgccatcttc ttcctgcctg atgaggggaa actacagcac ctggaaaatg aactcaccca 2400cgatatcatc accaagttcc tggaaaatga agacagaagg tctgccagct tacatttacc 2460caaactgtcc attactggaa cctatgatct gaagagcgtc ctgggtcaac tgggcatcac 2520taaggtcttc agcaatgggg ctgacctctc cggggtcaca gaggaggcac ccctgaagct 2580ctccaaggcc gtgcataagg ctgtgctgac catcgacgag aaagggactg aagctgctgg 2640ggccatgttt ttagaggcca tacccatgtc tatccccccc gaggtcaagt tcaacaaacc 2700ctttgtcttc ttaatgattg aacaaaatac caagtctccc ctcttcatgg gaaaagtggt 2760gaatcccacc caaaaataac tgcctctcgc tcctcaaccc ctcccctcca tccctggccc 2820cctccctgga tgacattaaa gaagggttga gctggtaacc cccccccccc ctgcaggggc 2880cctcgacccg ggcggccgct tcgagcagac atgataagat acattgatga gtttggacaa 2940accacaacta gaatgcagtg aaaaaaatgc tttatttgtg aaatttgtga tgctattgct 3000ttatttgtaa ccattataag ctgcaataaa caagttaaca acaacaattg cattcatttt 3060atgtttcagg ttcaggggga gatgtgggag gttttttaaa gcaagtaaaa cctctacaaa 3120tgtggtaaaa tcgataagga tctaggaacc cctagtgatg gagttggcca ctccctctct 3180gcgcgctcgc tcgctcactg aggccgcccg ggcaaagccc gggcgtcggg cgacctttgg 3240tcgcccggcc tcagtgagcg agcgagcgcg cagagaggga gtggccaacc cccccccccc 3300cccccctgca gcctggcgta atagcgaaga ggcccgcacc gatcgccctt cccaacagtt 3360gcgtagcctg aatggcgaat ggcgcgacgc gccctgtagc ggcgcattaa gcgcggcggg 3420tgtggtggtt acgcgcagcg tgaccgctac acttgccagc gccctagcgc ccgctccttt 3480cgctttcttc ccttcctttc tcgccacgtt cgccggcttt ccccgtcaag ctctaaatcg 3540ggggctccct ttagggttcc gatttagtgc tttacggcac ctcgacccca aaaaacttga 3600ttagggtgat ggttcacgta gtgggccatc gccctgatag acggtttttc gccctttgac 3660gttggagtcc acgttcttta atagtggact cttgttccaa actggaacaa cactcaaccc 3720tatctcggtc tattcttttg atttataagg gattttgccg atttcggcct attggttaaa 3780aaatgagctg atttaacaaa aatttaacgc gaattttaac aaaatattaa cgtttacaat 3840ttcctgatgc ggtattttct ccttacgcat ctgtgcggta tttcacaccg catatggtgc 3900actctcagta caatctgctc tgatgccgca tagttaagcc agccccgaca cccgccaaca 3960cccgctgacg cgccctgacg ggcttgtctg ctcccggcat ccgcttacag acaagctgtg 4020accgtctccg ggagctgcat gtgtcagagg ttttcaccgt catcaccgaa acgcgcgaga 4080cgaaagggcc tcgtgatacg cctattttta taggttaatg tcatgataat aatggtttct 4140tagacgtcag gtggcacttt tcggggaaat gtgcgcggaa cccctatttg tttatttttc 4200taaatacatt caaatatgta tccgctcatg agacaataac cctgataaat gcttcaataa 4260tattgaaaaa ggaagagtat gagtattcaa catttccgtg tcgcccttat tccctttttt 4320gcggcatttt gccttcctgt ttttgctcac ccagaaacgc tggtgaaagt aaaagatgct 4380gaagatcagt tgggtgcacg agtgggttac atcgaactgg atctcaacag cggtaagatc 4440cttgagagtt ttcgccccga agaacgtttt ccaatgatga gcacttttaa agttctgcta 4500tgtggcgcgg tattatcccg tattgacgcc gggcaagagc aactcggtcg ccgcatacac 4560tattctcaga atgacttggt tgagtactca ccagtcacag aaaagcatct tacggatggc 4620atgacagtaa gagaattatg cagtgctgcc ataaccatga gtgataacac tgcggccaac 4680ttacttctga caacgatcgg aggaccgaag gagctaaccg cttttttgca caacatgggg 4740gatcatgtaa ctcgccttga tcgttgggaa ccggagctga atgaagccat accaaacgac 4800gagcgtgaca ccacgatgcc tgtagcaatg gcaacaacgt tgcgcaaact attaactggc 4860gaactactta ctctagcttc ccggcaacaa ttaatagact ggatggaggc ggataaagtt 4920gcaggaccac ttctgcgctc ggcccttccg gctggctggt ttattgctga taaatctgga 4980gccggtgagc gtgggtctcg cggtatcatt gcagcactgg ggccagatgg taagccctcc 5040cgtatcgtag ttatctacac gacggggagt caggcaacta tggatgaacg aaatagacag 5100atcgctgaga taggtgcctc actgattaag cattggtaac tgtcagacca agtttactca 5160tatatacttt agattgattt aaaacttcat ttttaattta aaaggatcta ggtgaagatc 5220ctttttgata atctcatgac caaaatccct taacgtgagt tttcgttcca ctgagcgtca 5280gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcg cgtaatctgc 5340tgcttgcaaa caaaaaaacc accgctacca gcggtggttt gtttgccgga tcaagagcta 5400ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa tactgtcctt 5460ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc tacatacctc 5520gctctgctaa tcctgttacc agtggctgct gccagtggcg ataagtcgtg tcttaccggg 5580ttggactcaa gacgatagtt accggataag gcgcagcggt cgggctgaac ggggggttcg 5640tgcacacagc ccagcttgga gcgaacgacc tacaccgaac tgagatacct acagcgtgag 5700cattgagaaa gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc ggtaagcggc 5760agggtcggaa caggagagcg cacgagggag cttccagggg gaaacgcctg gtatctttat 5820agtcctgtcg ggtttcgcca cctctgactt gagcgtcgat ttttgtgatg ctcgtcaggg 5880gggcggagcc tatggaaaaa cgccagcaac gcggcctttt tacggttcct ggccttttgc 5940tggccttttg ctcacatgtt ctttcctgcg ttatcccctg attctgtgga taaccgtatt 6000accgcctttg agtgagctga taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca 6060gtgagcgagg aagcggaaga gcgcccaata cgcaaaccgc ctctccccgc gcgttggccg 6120attcattaat gcagggctgc ag 6142 9 6924 DNA Artificial Sequence Description of Artificial SequencePLASMID p43rmsENC-AT 9gggggggggg gggggggttg gccactccct ctctgcgcgc tcgctcgctc actgaggccg 60ggcgaccaaa ggtcgcccga cgcccgggct ttgcccgggc ggcctcagtg agcgagcgag 120cgcgcagaga gggagtggcc aactccatca ctaggggttc ctagatctga cacccaaata 180tggcctgggg tgaggaatgg tgccgtcgcc atatttgggt gtccaccatt cctcaccgct 240ctaaaaataa ctcccgggag ttatttttag agcgccaaca cctgctgcct gcccaccatt 300cctcaccgct ctaaaaataa ctccccacca ttcctcaccc gtcgccatat ttgggtgtcg 360tgaggaatgg tgagatcttc aatattggcc attagccata ttattcattg gttatatagc 420ataaatcaat attggctatt ggccattgca tacgttgtat ctatatcata atatgtacat 480ttatattggc tcatgtccaa tatgaccgcc atgttggcat tgattattga ctagttatta 540atagtaatca attacggggt cattagttca tagcccatat atggagttcc gcgttacata 600acttacggta aatggcccgc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat 660aatgacgtat gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga 720gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc caagtccgcc 780ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt 840acgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta ccatggtcga 900ggtgagcccc acgttctgct tcactctccc catctccccc ccctccccac ccccaatttt 960gtatttattt attttttaat tattttgtgc agcgatgggg gcgggggggg ggggggggcg 1020cgcgccaggc ggggcggggc ggggcgaggg gcggggcggg gcgaggcgga gaggtgcggc 1080ggcagccaat cagagcggcg cgctccgaaa gtttcctttt atggcgaggc ggcggcggcg 1140gcggccctat aaaaagcgaa gcgcgcggcg ggcgggagtc gctgcgacgc tgccttcgcc 1200ccgtgccccg ctccgccgcc gcctcgcgcc gcccgccccg gctctgactg accgcgttac 1260tcccacaggt gagcgggcgg gacggccctt ctcctccggg ctgtaattag cgcttggttt 1320aatgacggct tgtttctttt ctgtggctgc gtgaaagcct tgaggggctc cgggagggcc 1380ctttgtgcgg gggggagcgg ctcggggggt gcgtgcgtgt gtgtgtgcgt ggggagcgcc 1440gcgtgcggcc cgcgctgccc ggcggctgtg agcgctgcgg gcgcggcgcg gggctttgtg 1500cgctccgcag tgtgcgcgag gggagcgcgg ccgggggcgg tgccccgcgg tgcggggggg 1560gctgcgaggg gaacaaaggc tgcgtgcggg gtgtgtgcgt gggggggtga gcagggggtg 1620tgggcgcggc ggtcgggctg taaccccccc ctgcaccccc ctccccgagt tgctgagcac 1680ggcccggctt cgggtgcggg gctccgtacg gggcgtggcg cggggctcgc cgtgccgggc 1740ggggggtggc ggcaggtggg ggtgccgggc ggggcggggc cgcctcgggc cggggagggc 1800tcgggggagg ggcgcggcgg cccccggagc gccggcggct gtcgaggcgc ggcgagccgc 1860agccattgcc ttttatggta atcgtgcgag agggcgcagg gacttccttt gtcccaaatc 1920tgtgcggagc cgaaatctgg gaggcgccgc cgcaccccct ctagcgggcg cggggcgaag 1980cggtgcggcg ccggcaggaa ggaaatgggc ggggagggcc ttcgtgcgtc gccgcgccgc 2040cgtccccttc tccctctcca gcctcggggc tgtccgcggg gggacggctg ccttcggggg 2100ggacggggca gggcggggtt cggcttctgg cgtgtgaccg gcggctctag agcctctgct 2160aaccatgttc atgccttctt ctttttccta cagctcctgg gcaacgtgct ggttattgtg 2220ctgtctcatc attttggcaa agaattcgat atcaagcttg gggattttca ggcaccacca 2280ctgacctggg acagtgaatc gacaatgccg tcttctgtct cgtggggcat cctcctgctg 2340gcaggcctgt gctgcctggt ccctgtctcc ctggctgagg atccccaggg agatgctgcc 2400cagaagacag atacatccca ccatgatcag gatcacccaa ccttcaacaa gatcaccccc 2460aacctggctg agttcgcctt cagcctatac cgccagctgg cacaccagtc caacagcacc 2520aatatcttct tctccccagt gagcatcgct acagcctttg caatgctctc cctggggacc 2580aaggctgaca ctcacgatga aatcctggag ggcctgaatt tcaacctcac ggagattccg 2640gaggctcaga tccatgaagg cttccaggaa ctcctccgta ccctcaacca gccagacagc 2700cagctccagc tgaccaccgg caatggcctg ttcctcagcg agggcctgaa gctagtggat 2760aagtttttgg aggatgttaa aaagttgtac cactcagaag ccttcactgt caacttcggg 2820gacaccgaag aggccaagaa acagatcaac gattacgtgg agaagggtac tcaagggaaa 2880attgtggatt tggtcaagga gcttgacaga gacacagttt ttgctctggt gaattacatc 2940ttctttaaag gcaaatggga gagacccttt gaagtcaagg acaccgagga agaggacttc 3000cacgtggacc aggtgaccac cgtgaaggtg cctatgatga agcgtttagg catgtttaac 3060atccagcact gtaagaagct gtccagctgg gtgctgctga tgaaatacct gggcaatgcc 3120accgccatct tcttcctgcc tgatgagggg aaactacagc acctggaaaa tgaactcacc 3180cacgatatca tcaccaagtt cctggaaaat gaagacagaa ggtctgccag cttacattta 3240cccaaactgt ccattactgg aacctatgat ctgaagagcg tcctgggtca actgggcatc 3300actaaggtct tcagcaatgg ggctgacctc tccggggtca cagaggaggc acccctgaag 3360ctctccaagg ccgtgcataa ggctgtgctg accatcgacg agaaagggac tgaagctgct 3420ggggccatgt ttttagaggc catacccatg tctatccccc ccgaggtcaa gttcaacaaa 3480ccctttgtct tcttaatgat tgaacaaaat accaagtctc ccctcttcat gggaaaagtg 3540gtgaatccca cccaaaaata actgcctctc gctcctcaac ccctcccctc catccctggc 3600cccctccctg gatgacatta aagaagggtt gagctggtaa cccccccccc ccctgcaggg 3660gccctcgacc cgggcggccg cttcgagcag acatgataag atacattgat gagtttggac 3720aaaccacaac tagaatgcag tgaaaaaaat gctttatttg tgaaatttgt gatgctattg 3780ctttatttgt aaccattata agctgcaata aacaagttaa caacaacaat tgcattcatt 3840ttatgtttca ggttcagggg gagatgtggg aggtttttta aagcaagtaa aacctctaca 3900aatgtggtaa aatcgataag gatctaggaa cccctagtga tggagttggc cactccctct 3960ctgcgcgctc gctcgctcac tgaggccgcc cgggcaaagc ccgggcgtcg ggcgaccttt 4020ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa cccccccccc 4080cccccccctg cagcctggcg taatagcgaa gaggcccgca ccgatcgccc ttcccaacag 4140ttgcgtagcc tgaatggcga atggcgcgac gcgccctgta gcggcgcatt aagcgcggcg 4200ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca gcgccctagc gcccgctcct 4260ttcgctttct tcccttcctt tctcgccacg ttcgccggct ttccccgtca agctctaaat 4320cgggggctcc ctttagggtt ccgatttagt gctttacggc acctcgaccc caaaaaactt 4380gattagggtg atggttcacg tagtgggcca tcgccctgat agacggtttt tcgccctttg 4440acgttggagt ccacgttctt taatagtgga ctcttgttcc aaactggaac aacactcaac 4500cctatctcgg tctattcttt tgatttataa gggattttgc cgatttcggc ctattggtta 4560aaaaatgagc tgatttaaca aaaatttaac gcgaatttta acaaaatatt aacgtttaca 4620atttcctgat gcggtatttt ctccttacgc atctgtgcgg tatttcacac cgcatatggt 4680gcactctcag tacaatctgc tctgatgccg catagttaag ccagccccga cacccgccaa 4740cacccgctga cgcgccctga cgggcttgtc tgctcccggc atccgcttac agacaagctg 4800tgaccgtctc cgggagctgc atgtgtcaga ggttttcacc gtcatcaccg aaacgcgcga 4860gacgaaaggg cctcgtgata cgcctatttt tataggttaa tgtcatgata ataatggttt 4920cttagacgtc aggtggcact tttcggggaa atgtgcgcgg aacccctatt tgtttatttt 4980tctaaataca ttcaaatatg tatccgctca tgagacaata accctgataa atgcttcaat 5040aatattgaaa aaggaagagt atgagtattc aacatttccg tgtcgccctt attccctttt 5100ttgcggcatt ttgccttcct gtttttgctc acccagaaac gctggtgaaa gtaaaagatg 5160ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga 5220tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc 5280tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga gcaactcggt cgccgcatac 5340actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg 5400gcatgacagt aagagaatta tgcagtgctg ccataaccat gagtgataac actgcggcca 5460acttacttct gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg 5520gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg 5580acgagcgtga caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg 5640gcgaactact tactctagct tcccggcaac aattaataga ctggatggag gcggataaag 5700ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg 5760gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct 5820cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac 5880agatcgctga gataggtgcc tcactgatta agcattggta actgtcagac caagtttact 5940catatatact ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga 6000tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt 6060cagaccccgt agaaaagatc aaaggatctt cttgagatcc tttttttctg cgcgtaatct 6120gctgcttgca aacaaaaaaa ccaccgctac cagcggtggt ttgtttgccg gatcaagagc 6180taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgtcc 6240ttctagtgta gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc 6300tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg 6360ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga acggggggtt 6420cgtgcacaca gcccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg 6480agcattgaga aagcgccacg cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg 6540gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggtatcttt 6600atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga tgctcgtcag 6660gggggcggag cctatggaaa aacgccagca acgcggcctt tttacggttc ctggcctttt 6720gctggccttt tgctcacatg ttctttcctg cgttatcccc tgattctgtg gataaccgta 6780ttaccgcctt tgagtgagct gataccgctc gccgcagccg aacgaccgag cgcagcgagt 6840cagtgagcga ggaagcggaa gagcgcccaa tacgcaaacc gcctctcccc gcgcgttggc 6900cgattcatta atgcagggct gcag 6924 10 6924 DNA Artificial Sequence Description of Artificial SequencePLASMID p43msENCB-AT 10gggggggggg gggggggttg gccactccct ctctgcgcgc tcgctcgctc actgaggccg 60ggcgaccaaa ggtcgcccga cgcccgggct ttgcccgggc ggcctcagtg agcgagcgag 120cgcgcagaga gggagtggcc aactccatca ctaggggttc ctagatctca ccattcctca 180cgacacccaa atatggcgac gggtgaggaa tggtggggag ttatttttag agcggtgagg 240aatggtgggc aggcagcagg tgttggcgct ctaaaaataa ctcccgggag ttatttttag 300agcggtgagg aatggtggac acccaaatat ggcgacggca ccattcctca ccccaggcca 360tatttgggtg tcagatcttc aatattggcc attagccata ttattcattg gttatatagc 420ataaatcaat attggctatt ggccattgca tacgttgtat ctatatcata atatgtacat 480ttatattggc tcatgtccaa tatgaccgcc atgttggcat tgattattga ctagttatta 540atagtaatca attacggggt cattagttca tagcccatat atggagttcc gcgttacata 600acttacggta aatggcccgc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat 660aatgacgtat gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga 720gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc caagtccgcc 780ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt 840acgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta ccatggtcga 900ggtgagcccc acgttctgct tcactctccc catctccccc ccctccccac ccccaatttt 960gtatttattt attttttaat tattttgtgc agcgatgggg gcgggggggg ggggggggcg 1020cgcgccaggc ggggcggggc ggggcgaggg gcggggcggg gcgaggcgga gaggtgcggc 1080ggcagccaat cagagcggcg cgctccgaaa gtttcctttt atggcgaggc ggcggcggcg 1140gcggccctat aaaaagcgaa gcgcgcggcg ggcgggagtc gctgcgacgc tgccttcgcc 1200ccgtgccccg ctccgccgcc gcctcgcgcc gcccgccccg gctctgactg accgcgttac 1260tcccacaggt gagcgggcgg gacggccctt ctcctccggg ctgtaattag cgcttggttt 1320aatgacggct tgtttctttt ctgtggctgc gtgaaagcct tgaggggctc cgggagggcc 1380ctttgtgcgg gggggagcgg ctcggggggt gcgtgcgtgt gtgtgtgcgt ggggagcgcc 1440gcgtgcggcc cgcgctgccc ggcggctgtg agcgctgcgg gcgcggcgcg gggctttgtg 1500cgctccgcag tgtgcgcgag gggagcgcgg ccgggggcgg tgccccgcgg tgcggggggg 1560gctgcgaggg gaacaaaggc tgcgtgcggg gtgtgtgcgt gggggggtga gcagggggtg 1620tgggcgcggc ggtcgggctg taaccccccc ctgcaccccc ctccccgagt tgctgagcac 1680ggcccggctt cgggtgcggg gctccgtacg gggcgtggcg cggggctcgc cgtgccgggc 1740ggggggtggc ggcaggtggg ggtgccgggc ggggcggggc cgcctcgggc cggggagggc 1800tcgggggagg ggcgcggcgg cccccggagc gccggcggct gtcgaggcgc ggcgagccgc 1860agccattgcc ttttatggta atcgtgcgag agggcgcagg gacttccttt gtcccaaatc 1920tgtgcggagc cgaaatctgg gaggcgccgc cgcaccccct ctagcgggcg cggggcgaag 1980cggtgcggcg ccggcaggaa ggaaatgggc ggggagggcc ttcgtgcgtc gccgcgccgc 2040cgtccccttc tccctctcca gcctcggggc tgtccgcggg gggacggctg ccttcggggg 2100ggacggggca gggcggggtt cggcttctgg cgtgtgaccg gcggctctag agcctctgct 2160aaccatgttc atgccttctt ctttttccta cagctcctgg gcaacgtgct ggttattgtg 2220ctgtctcatc attttggcaa agaattcgat atcaagcttg gggattttca ggcaccacca 2280ctgacctggg acagtgaatc gacaatgccg tcttctgtct cgtggggcat cctcctgctg 2340gcaggcctgt gctgcctggt ccctgtctcc ctggctgagg atccccaggg agatgctgcc 2400cagaagacag atacatccca ccatgatcag gatcacccaa ccttcaacaa gatcaccccc 2460aacctggctg agttcgcctt cagcctatac cgccagctgg cacaccagtc caacagcacc 2520aatatcttct tctccccagt gagcatcgct acagcctttg caatgctctc cctggggacc 2580aaggctgaca ctcacgatga aatcctggag ggcctgaatt tcaacctcac ggagattccg 2640gaggctcaga tccatgaagg cttccaggaa ctcctccgta ccctcaacca gccagacagc 2700cagctccagc tgaccaccgg caatggcctg ttcctcagcg agggcctgaa gctagtggat 2760aagtttttgg aggatgttaa aaagttgtac cactcagaag ccttcactgt caacttcggg 2820gacaccgaag aggccaagaa acagatcaac gattacgtgg agaagggtac tcaagggaaa 2880attgtggatt tggtcaagga gcttgacaga gacacagttt ttgctctggt gaattacatc 2940ttctttaaag gcaaatggga gagacccttt gaagtcaagg acaccgagga agaggacttc 3000cacgtggacc aggtgaccac cgtgaaggtg cctatgatga agcgtttagg catgtttaac 3060atccagcact gtaagaagct gtccagctgg gtgctgctga tgaaatacct gggcaatgcc 3120accgccatct tcttcctgcc tgatgagggg aaactacagc acctggaaaa tgaactcacc 3180cacgatatca tcaccaagtt cctggaaaat gaagacagaa ggtctgccag cttacattta 3240cccaaactgt ccattactgg aacctatgat ctgaagagcg tcctgggtca actgggcatc 3300actaaggtct tcagcaatgg ggctgacctc tccggggtca cagaggaggc acccctgaag 3360ctctccaagg ccgtgcataa ggctgtgctg accatcgacg agaaagggac tgaagctgct 3420ggggccatgt ttttagaggc catacccatg tctatccccc ccgaggtcaa gttcaacaaa 3480ccctttgtct tcttaatgat tgaacaaaat accaagtctc ccctcttcat gggaaaagtg 3540gtgaatccca cccaaaaata actgcctctc gctcctcaac ccctcccctc catccctggc 3600cccctccctg gatgacatta aagaagggtt gagctggtaa cccccccccc ccctgcaggg 3660gccctcgacc cgggcggccg cttcgagcag acatgataag atacattgat gagtttggac 3720aaaccacaac tagaatgcag tgaaaaaaat gctttatttg tgaaatttgt gatgctattg 3780ctttatttgt aaccattata agctgcaata aacaagttaa caacaacaat tgcattcatt 3840ttatgtttca ggttcagggg gagatgtggg aggtttttta aagcaagtaa aacctctaca 3900aatgtggtaa aatcgataag gatctaggaa cccctagtga tggagttggc cactccctct 3960ctgcgcgctc gctcgctcac tgaggccgcc cgggcaaagc ccgggcgtcg ggcgaccttt 4020ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa cccccccccc 4080cccccccctg cagcctggcg taatagcgaa gaggcccgca ccgatcgccc ttcccaacag 4140ttgcgtagcc tgaatggcga atggcgcgac gcgccctgta gcggcgcatt aagcgcggcg 4200ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca gcgccctagc gcccgctcct 4260ttcgctttct tcccttcctt tctcgccacg ttcgccggct ttccccgtca agctctaaat 4320cgggggctcc ctttagggtt ccgatttagt gctttacggc acctcgaccc caaaaaactt 4380gattagggtg atggttcacg tagtgggcca tcgccctgat agacggtttt tcgccctttg 4440acgttggagt ccacgttctt taatagtgga ctcttgttcc aaactggaac aacactcaac 4500cctatctcgg tctattcttt tgatttataa gggattttgc cgatttcggc ctattggtta 4560aaaaatgagc tgatttaaca aaaatttaac gcgaatttta acaaaatatt aacgtttaca 4620atttcctgat gcggtatttt ctccttacgc atctgtgcgg tatttcacac cgcatatggt 4680gcactctcag tacaatctgc tctgatgccg catagttaag ccagccccga cacccgccaa 4740cacccgctga cgcgccctga cgggcttgtc tgctcccggc atccgcttac agacaagctg 4800tgaccgtctc cgggagctgc atgtgtcaga ggttttcacc gtcatcaccg aaacgcgcga 4860gacgaaaggg cctcgtgata cgcctatttt tataggttaa tgtcatgata ataatggttt 4920cttagacgtc aggtggcact tttcggggaa atgtgcgcgg aacccctatt tgtttatttt 4980tctaaataca ttcaaatatg tatccgctca tgagacaata accctgataa atgcttcaat 5040aatattgaaa aaggaagagt atgagtattc aacatttccg tgtcgccctt attccctttt 5100ttgcggcatt ttgccttcct gtttttgctc acccagaaac gctggtgaaa gtaaaagatg 5160ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga 5220tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc 5280tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga gcaactcggt cgccgcatac 5340actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg 5400gcatgacagt aagagaatta tgcagtgctg ccataaccat gagtgataac actgcggcca 5460acttacttct gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg 5520gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg 5580acgagcgtga caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg 5640gcgaactact tactctagct tcccggcaac aattaataga ctggatggag gcggataaag 5700ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg 5760gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct 5820cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac 5880agatcgctga gataggtgcc tcactgatta agcattggta actgtcagac caagtttact 5940catatatact ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga 6000tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt 6060cagaccccgt agaaaagatc aaaggatctt cttgagatcc tttttttctg cgcgtaatct 6120gctgcttgca aacaaaaaaa ccaccgctac cagcggtggt ttgtttgccg gatcaagagc 6180taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgtcc 6240ttctagtgta gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc 6300tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg 6360ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga acggggggtt 6420cgtgcacaca gcccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg 6480agcattgaga aagcgccacg cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg 6540gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggtatcttt 6600atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga tgctcgtcag 6660gggggcggag cctatggaaa aacgccagca acgcggcctt tttacggttc ctggcctttt 6720gctggccttt tgctcacatg ttctttcctg cgttatcccc tgattctgtg gataaccgta 6780ttaccgcctt tgagtgagct gataccgctc gccgcagccg aacgaccgag cgcagcgagt 6840cagtgagcga ggaagcggaa gagcgcccaa tacgcaaacc gcctctcccc gcgcgttggc 6900cgattcatta atgcagggct gcag 6924 11 6924 DNA Artificial Sequence Description of Artificial SequencePLASMID p43rmsENCB-AT 11gggggggggg gggggggttg gccactccct ctctgcgcgc tcgctcgctc actgaggccg 60ggcgaccaaa ggtcgcccga cgcccgggct ttgcccgggc ggcctcagtg agcgagcgag 120cgcgcagaga gggagtggcc aactccatca ctaggggttc ctagatctga cacccaaata 180tggcctgggg tgaggaatgg tgccgtcgcc atatttgggt gtccaccatt cctcaccgct 240ctaaaaataa ctcccgggag ttatttttag agcgccaaca cctgctgcct gcccaccatt 300cctcaccgct ctaaaaataa ctccccacca ttcctcaccc gtcgccatat ttgggtgtcg 360tgaggaatgg tgagatcttc aatattggcc attagccata ttattcattg gttatatagc 420ataaatcaat attggctatt ggccattgca tacgttgtat ctatatcata atatgtacat 480ttatattggc tcatgtccaa tatgaccgcc atgttggcat tgattattga ctagttatta 540atagtaatca attacggggt cattagttca tagcccatat atggagttcc gcgttacata 600acttacggta aatggcccgc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat 660aatgacgtat gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga 720gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc caagtccgcc 780ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt 840acgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta ccatggtcga 900ggtgagcccc acgttctgct tcactctccc catctccccc ccctccccac ccccaatttt 960gtatttattt attttttaat tattttgtgc agcgatgggg gcgggggggg ggggggggcg 1020cgcgccaggc ggggcggggc ggggcgaggg gcggggcggg gcgaggcgga gaggtgcggc 1080ggcagccaat cagagcggcg cgctccgaaa gtttcctttt atggcgaggc ggcggcggcg 1140gcggccctat aaaaagcgaa gcgcgcggcg ggcgggagtc gctgcgacgc tgccttcgcc 1200ccgtgccccg ctccgccgcc gcctcgcgcc gcccgccccg gctctgactg accgcgttac 1260tcccacaggt gagcgggcgg gacggccctt ctcctccggg ctgtaattag cgcttggttt 1320aatgacggct tgtttctttt ctgtggctgc gtgaaagcct tgaggggctc cgggagggcc 1380ctttgtgcgg gggggagcgg ctcggggggt gcgtgcgtgt gtgtgtgcgt ggggagcgcc 1440gcgtgcggcc cgcgctgccc ggcggctgtg agcgctgcgg gcgcggcgcg gggctttgtg 1500cgctccgcag tgtgcgcgag gggagcgcgg ccgggggcgg tgccccgcgg tgcggggggg 1560gctgcgaggg gaacaaaggc tgcgtgcggg gtgtgtgcgt gggggggtga gcagggggtg 1620tgggcgcggc ggtcgggctg taaccccccc ctgcaccccc ctccccgagt tgctgagcac 1680ggcccggctt cgggtgcggg gctccgtacg gggcgtggcg cggggctcgc cgtgccgggc 1740ggggggtggc ggcaggtggg ggtgccgggc ggggcggggc cgcctcgggc cggggagggc 1800tcgggggagg ggcgcggcgg cccccggagc gccggcggct gtcgaggcgc ggcgagccgc 1860agccattgcc ttttatggta atcgtgcgag agggcgcagg gacttccttt gtcccaaatc 1920tgtgcggagc cgaaatctgg gaggcgccgc cgcaccccct ctagcgggcg cggggcgaag 1980cggtgcggcg ccggcaggaa ggaaatgggc ggggagggcc ttcgtgcgtc gccgcgccgc 2040cgtccccttc tccctctcca gcctcggggc tgtccgcggg gggacggctg ccttcggggg 2100ggacggggca gggcggggtt cggcttctgg cgtgtgaccg gcggctctag agcctctgct 2160aaccatgttc atgccttctt ctttttccta cagctcctgg gcaacgtgct ggttattgtg 2220ctgtctcatc attttggcaa agaattcgat atcaagcttg gggattttca ggcaccacca 2280ctgacctggg acagtgaatc gacaatgccg tcttctgtct cgtggggcat cctcctgctg 2340gcaggcctgt gctgcctggt ccctgtctcc ctggctgagg atccccaggg agatgctgcc 2400cagaagacag atacatccca ccatgatcag gatcacccaa ccttcaacaa gatcaccccc 2460aacctggctg agttcgcctt cagcctatac cgccagctgg cacaccagtc caacagcacc 2520aatatcttct tctccccagt gagcatcgct acagcctttg caatgctctc cctggggacc 2580aaggctgaca ctcacgatga aatcctggag ggcctgaatt tcaacctcac ggagattccg 2640gaggctcaga tccatgaagg cttccaggaa ctcctccgta ccctcaacca gccagacagc 2700cagctccagc tgaccaccgg caatggcctg ttcctcagcg agggcctgaa gctagtggat 2760aagtttttgg aggatgttaa aaagttgtac cactcagaag ccttcactgt caacttcggg 2820gacaccgaag aggccaagaa acagatcaac gattacgtgg agaagggtac tcaagggaaa 2880attgtggatt tggtcaagga gcttgacaga gacacagttt ttgctctggt gaattacatc 2940ttctttaaag gcaaatggga gagacccttt gaagtcaagg acaccgagga agaggacttc 3000cacgtggacc aggtgaccac cgtgaaggtg cctatgatga agcgtttagg catgtttaac 3060atccagcact gtaagaagct gtccagctgg gtgctgctga tgaaatacct gggcaatgcc 3120accgccatct tcttcctgcc tgatgagggg aaactacagc acctggaaaa tgaactcacc 3180cacgatatca tcaccaagtt cctggaaaat gaagacagaa ggtctgccag cttacattta 3240cccaaactgt ccattactgg aacctatgat ctgaagagcg tcctgggtca actgggcatc 3300actaaggtct tcagcaatgg ggctgacctc tccggggtca cagaggaggc acccctgaag 3360ctctccaagg ccgtgcataa ggctgtgctg accatcgacg agaaagggac tgaagctgct 3420ggggccatgt ttttagaggc catacccatg tctatccccc ccgaggtcaa gttcaacaaa 3480ccctttgtct tcttaatgat tgaacaaaat accaagtctc ccctcttcat gggaaaagtg 3540gtgaatccca cccaaaaata actgcctctc gctcctcaac ccctcccctc catccctggc 3600cccctccctg gatgacatta aagaagggtt gagctggtaa cccccccccc ccctgcaggg 3660gccctcgacc cgggcggccg cttcgagcag acatgataag atacattgat gagtttggac 3720aaaccacaac tagaatgcag tgaaaaaaat gctttatttg tgaaatttgt gatgctattg 3780ctttatttgt aaccattata agctgcaata aacaagttaa caacaacaat tgcattcatt 3840ttatgtttca ggttcagggg gagatgtggg aggtttttta aagcaagtaa aacctctaca 3900aatgtggtaa aatcgataag gatctaggaa cccctagtga tggagttggc cactccctct 3960ctgcgcgctc gctcgctcac tgaggccgcc cgggcaaagc ccgggcgtcg ggcgaccttt 4020ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa cccccccccc 4080cccccccctg cagcctggcg taatagcgaa gaggcccgca ccgatcgccc ttcccaacag 4140ttgcgtagcc tgaatggcga atggcgcgac gcgccctgta gcggcgcatt aagcgcggcg 4200ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca gcgccctagc gcccgctcct 4260ttcgctttct tcccttcctt tctcgccacg ttcgccggct ttccccgtca agctctaaat 4320cgggggctcc ctttagggtt ccgatttagt gctttacggc acctcgaccc caaaaaactt 4380gattagggtg atggttcacg tagtgggcca tcgccctgat agacggtttt tcgccctttg 4440acgttggagt ccacgttctt taatagtgga ctcttgttcc aaactggaac aacactcaac 4500cctatctcgg tctattcttt tgatttataa gggattttgc cgatttcggc ctattggtta 4560aaaaatgagc tgatttaaca aaaatttaac gcgaatttta acaaaatatt aacgtttaca 4620atttcctgat gcggtatttt ctccttacgc atctgtgcgg tatttcacac cgcatatggt 4680gcactctcag tacaatctgc tctgatgccg catagttaag ccagccccga cacccgccaa 4740cacccgctga cgcgccctga cgggcttgtc tgctcccggc atccgcttac agacaagctg 4800tgaccgtctc cgggagctgc atgtgtcaga ggttttcacc gtcatcaccg aaacgcgcga 4860gacgaaaggg cctcgtgata cgcctatttt tataggttaa tgtcatgata ataatggttt 4920cttagacgtc aggtggcact tttcggggaa atgtgcgcgg aacccctatt tgtttatttt 4980tctaaataca ttcaaatatg tatccgctca tgagacaata accctgataa atgcttcaat 5040aatattgaaa aaggaagagt atgagtattc aacatttccg tgtcgccctt attccctttt 5100ttgcggcatt ttgccttcct gtttttgctc acccagaaac gctggtgaaa gtaaaagatg 5160ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga 5220tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc 5280tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga gcaactcggt cgccgcatac 5340actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg 5400gcatgacagt aagagaatta tgcagtgctg ccataaccat gagtgataac actgcggcca 5460acttacttct gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg 5520gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg 5580acgagcgtga caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg 5640gcgaactact tactctagct tcccggcaac aattaataga ctggatggag gcggataaag 5700ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg 5760gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct 5820cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac 5880agatcgctga gataggtgcc tcactgatta agcattggta actgtcagac caagtttact 5940catatatact ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga 6000tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt 6060cagaccccgt agaaaagatc aaaggatctt cttgagatcc tttttttctg cgcgtaatct 6120gctgcttgca aacaaaaaaa ccaccgctac cagcggtggt ttgtttgccg gatcaagagc 6180taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgtcc 6240ttctagtgta gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc 6300tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg 6360ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga acggggggtt 6420cgtgcacaca gcccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg 6480agcattgaga aagcgccacg cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg 6540gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggtatcttt 6600atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga tgctcgtcag 6660gggggcggag cctatggaaa aacgccagca acgcggcctt tttacggttc ctggcctttt 6720gctggccttt tgctcacatg ttctttcctg cgttatcccc tgattctgtg gataaccgta 6780ttaccgcctt tgagtgagct gataccgctc gccgcagccg aacgaccgag cgcagcgagt 6840cagtgagcga ggaagcggaa gagcgcccaa tacgcaaacc gcctctcccc gcgcgttggc 6900cgattcatta atgcagggct gcag 6924 12 20 DNA Artificial Sequence Description of Artificial SequenceSYNTHETIC PRIMER 12tatgggatcg gccattgaac 20 13 20 DNA Artificial Sequence Description of Artificial SequenceSYNTHETIC PRIMER 13cctgatgctc ttcgtccaga 20

Claims

1. A method for providing a mammal with a therapeutically effective amount of an alpha-1-antitrypsin protein, comprising introducing into suitable cells of said mammal an effective amount of an adeno-associated viral vector or an adeno-associated viral particle that comprises said vector; wherein said vector comprises a polynucleotide encoding an alpha-1-antitrypsin protein wherein said protein is expressed in said cell.

2. The method of claim 1, wherein said vector comprises a promoter operably linked to said polynucleotide.

3. The method of claim 2, wherein said promoter is selected from the group consisting of a CMV promoter, a hybrid CMV enhancer/β-actin promoter, an EF1 promoter, an U1a promoter and an U1b promoter.

4. The method of claim 2, wherein said promoter is an inducible promoter selected from the group consisting of a Tet-inducible promoter and a VP16-LexA promoter.

5. The method of claim 2, wherein said vector further comprises an enhancer sequence operably linked to said promoter.

6. The method of claim 5, wherein said enhancer is a CMV enhancer.

7. The method of claim 5, wherein said enhancer is a synthetic enhancer.

8. The method of claim 7, wherein said enhancer is a muscle-specific enhancer.

9. The method of claim 1, wherein said vector comprises an intron sequence.

10. The method of claim 9, wherein said intron sequence is intron II from a human alpha-1-antitrypsin gene.

11. The method of claim 1, wherein said vector comprises a polynucleotide encoding a human alpha-1-antitrypsin protein.

12. The method of claim 1, wherein said vector is selected from the group consisting of dE-AT (SEQ ID NO:3), E-AT (SEQ ID NO:2), C-AT (SEQ ID NO:1), C-AT2 (SEQ ID NO:7), p43C-AT (SEQ ID NO:4), p43CB-AT (SEQ ID NO:6), p43C-AT-IN (SEQ ID NO:5), p43msENC-AT (SEQ ID NO:8), p43rmsENC-AT (SEQ ID NO:9), p43msENCB-AT (SEQ ID NO:10) and p43rmsENCB-AT (SEQ ID NO:11).

13. The method of claim 1, wherein said mammal has a condition that results in a defective alpha-1-antitrypsin protein.

14. The method of claim 1, wherein said mammal has a condition that results in a deficiency of said alpha-1-antitrypsin protein.

15. The method of claim 1, wherein said mammal is a human.

16. The method of claim 1, wherein said adeno-associated viral vector or adeno-associated viral particle is introduced into myofibers, myoblasts, hepatocytes, or lung cells of said mammal.

17. The method of claim 1, wherein the adeno-associated viral particle is introduced into said cells by infection.

18. The method of claim 1, wherein the adeno-associated viral vector is introduced into said cells by transfection.

19. The method of claim 1, wherein said adeno-associated viral particle or adeno-associated viral vector is introduced into cells of said mammal in vitro and the transduced cells are then introduced into said mammal.

20. The method of claim 1, wherein said adeno-associated viral particle or adeno-associated viral vector is introduced into said cells in vivo.

21. The method of claim 20, wherein said adeno-associated viral particle or adeno-associated viral vector is injected into a muscle of said mammal.

22. The method of claim 20, wherein said adeno-associated viral particle or adeno-associated viral vector is injected into a portal or peripheral vein of said mammal.

23. The method of claim 20, wherein said adeno-associated viral particle or adeno-associated viral vector is injected intratracheally or inhaled into the lungs of said mammal.

24. A method for treating alpha-1-antitrypsin deficiency in a mammal, comprising introducing into suitable cells of said mammal an effective amount of an adeno-associated viral vector or an adeno-associated viral particle that comprises said vector; wherein said vector comprises a polynucleotide encoding an alpha-1-antitrypsin protein wherein said protein is expressed in said cell.

25. The method of claim 24, wherein said mammal is a human.

26. The method of claim 24, wherein said vector comprises a polynucleotide encoding a human alpha-1-antitrypsin protein.

27. The method of claim 24, wherein said alpha-1-antitrypsin deficiency is caused by a defective alpha-1-antitrypsin protein.